document incorporate reference document proxy statement annual meeting iii shareholder hold file securities exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm bsupplementary datum item change disagreement accountant account financial disclosure item control procedure management report item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel company incorporate new jersey financial information information company segment item management discussion analysis financial condition result operation item financial statement supplementary datum product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner product sale sale company pharmaceutical product total sale animal health consumer care product follow million total sale pharmaceutical januvia zetia remicade gardasil janumet isentress vytorin nasonex proquadmmr iivarivax singulair animal health consumer care revenue revenue primarily comprise alliance revenue miscellaneous corporate revenue thirdparty manufacturing sale october company divest substantial portion thirdparty manufacturing sale table content pharmaceutical company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder certain product company franchise follow primary care women health cardiovascular zetia ezetimibe market ezetrol outside united states vytorin ezetimibesimvastatin market inegy outside united states cholesterol modifying medicine diabete obesity januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes respiratory nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptom singulair montelukast medicine indicate chronic treatment asthma relief symptom allergic rhinitis dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma asmanex twisthaler mometasone furoate inhalation powder inhale corticosteroid firstline maintenance treatment asthma patient year age old women health endocrine nuvare etonogestrelethinyl estradiol vaginal ring vaginal contraceptive ring fosamax alendronate sodium treatment prevention osteoporosis follistim follitropin beta injection fertility treatment implanon etonogestrel implant singlerod subdermal contraceptive implant cerazette desogestrel progestin oral contraceptive arcoxia etoricoxib treatment arthritis pain company market outside united states avelox moxifloxacin broadspectrum fluoroquinolone antibiotic treatment certain respiratory skin infection company markets united states hospital specialty immunology remicade infliximab simponi golimumab treatment inflammatory disease company market europe russia turkey infectious disease isentress raltegravir antiretroviral therapy use combination therapy treatment hiv infection cancida caspofungin acetate antifungal product pegintron peginterferon alphab treatment chronic hepatitis invanz ertapenem sodium treatment certain infection victreli boceprevir treatment chronic hepatitis noxafil posaconazole prevention invasive fungal infection oncology temodar temozolomide market temodal outside united states treatment certain type brain tumor emend aprepitant prevention chemotherapyinduce postoperative nausea vomit cosopt dorzolamide hydrochloridetimolol maleate ophthalmic solution company market outside united states trusopt dorzolamide hydrochloride ophthalmic solution ophthalmic product bridion sugammadex sodium injection medication reversal certain muscle relaxant surgery integrilin eptifibatide treatment patient acute coronary syndrome diversify brand cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatment hypertension primaxin imipenem cilastatin sodium antibacterial product zocor simvastatin statin modifying cholesterol propecia finasteride product treatment male pattern hair loss clarinex desloratadine nonsedate antihistamine remeron mirtazapine antidepressant claritin loratadine treatment seasonal outdoor allergy yearround indoor allergy proscar finasteride urology product treatment symptomatic benign prostate enlargement maxalt rizatriptan benzoate product acute treatment migraine vaccine gardasil human papillomavirus quadrivalent type vaccine recombinant vaccine help prevent certain disease cause type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump table content rubella varicella mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella zostavax zoster vaccine live vaccine help prevent shingles herpe zoster pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child animal health animal health segment discover develop manufacture market animal health product include vaccine principal product segment include livestock product nuflor antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorder cattle regumatematrix fertility management swine horse resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo bovine respiratory disease zilmax revalor improve production efficiency beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious disease swine poultry product nobilisinnovax vaccine line poultry paracox coccivac coccidiosis vaccine companion animal product nobivac vaccine line flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabete mellitus treatment dog cat panacursafeguard broadspectrum anthelmintic dewormer use animal activylscaliborexspot protect bite flea tick mosquitoe sandfly aquaculture product slice parasiticide sea lice salmon aquavacnorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor antibiotic farmraised fish consumer care consumer care segment develop manufacture market overthecounter foot care sun care product principal product segment include overthecounter product claritin nondrowsy antihistamine miralax relief occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray zegerid otc treatment frequent heartburn oxytrol woman treatment overactive bladder woman foot care scholl foot care product lotrimin topical antifungal product tinactin topical antifungal product foot sneaker odorwetness product sun care coppertone sun care lotion spray dry oil discussion sale company product item management discussion analysis financial condition result operation joint venture astrazeneca merck enter agreement astra astra develop market astra product united states merck astra form equally own joint venture develop market astra new prescription medicine united states include prilosec omeprazole class medication know proton pump inhibitor slow production acid cell stomach lining merck astra restructure joint venture merck acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right table content company earn certain partnership return ongoing revenue base sale kbi product partnership return include priority return provide partnership agreement preferential return represent company share undistribute partnership azlp generally accept accounting principle gaap earning variable return relate companys limited partner interest astrazeneca option purchase merck interest kbi base value merck interest nexium prilosec astrazenecas option exercisable march april astrazeneca choose exercise option closing date expect june amend agreement astrazeneca payment merck closing million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june exercise price include additional equal multiple time merck average annual profit allocation partnership year prior exercise company believe likely astrazeneca exercise option astrazeneca exercise option company long record equity income azlp supply sale azlp terminate addition company recognize noncash pretax gain approximately million sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution thenexiste european union european free trade association merck sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory license subsidiary scheringplough corporation scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease schere ploughs subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company exclusive marketing right product europe russia turkey december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system october european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi follow receipt pricing reimbursement approval profit derive merck exclusive distribution product country equally divide merck competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug consumer animal health care manufacturer company operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect intangible asset table content associate certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor company consumer care operation face competition consumer health care business retailer carry private label brand companys competitive position affect factor include regulatory legislative issue scientific technological advance quality price company product promotional effort growth low cost private label brand health care environment global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient backdrop united states enact major health care reform legislation began implement insurance market reform advance continue implementation law expect expand access health care million americans end decade previously insurance coverage respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual health care reform fee total annual industry fee billion billion fee assess company proportion share sale certain government program medicare medicaid company record million million million cost marketing administrative expense respectively annual health care reform fee impact health care reform predict time company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue table content generate cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company effort health care cost containment remain intense european country country continue announce execute austerity measure include implementation pricing action reduce price generic patent drug mandatory switch generic drug company take step mitigate impact country austerity measure continue negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance addition majority country attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug brand authority use price data market set new local price brandname drug include company guideline examine reference pricing usually set local market change pursuant local regulation addition japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine furthermore government order repricing class drug determine appropriate applicable rule certain market outside united states implement cost management strategy health technology assessment require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement company focus share revenue emerge market increase government emerge market focus constrain health care cost enact price control relate measure compulsory license aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force government regulation pharmaceutical industry subject regulation regional country state local agency world governmental regulation legislation tend focus standard process determine drug safety effectiveness condition sale reimbursement especially relate pricing product particular importance food drug administration fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription table content pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition company farreache philanthropic program merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccine merck announce launch merck mother longterm effort global health partner end preventable death complication pregnancy childbirth initiative merck leverage scientific business expertise help prove solution widely available develop new technology improve public policymaker awareness issue merck past provide fund merck foundation independent organization partner variety organization dedicate improve global health partnership african comprehensive hivaids partnership botswana collaboration government botswana renew support botswana response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy datum protection company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include recently enact law regulation united states europe asia latin america increase enforcement litigation activity united states develop market distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer companys overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business table content patent trademark license patent protection consider aggregate material importance company marketing product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant current patent law provide additional patent term patent term restoration period patent product regulatory review fda patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection include patent term restoration pediatric exclusivity major market product product year expiration asmanex use formulation dulera useformulation combination integrilin compound useformulation nasonex useformulationformulation emend follistim pegintron conjugate mature ifnalpha invanz compound composition zostavax use zetiavytorinliptruzet nuvare delivery system emend injection noxafil rotateq intron recombivax method makingvectors januviajanumetjanumet compound salt zioptan pende patent term restoration isentress victrelis pende patent term restoration gardasil compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability agreement apotex generic manufacturer grant right merck nasonex use patent united states addition district court decision uphold appeal court appeal federal circuit find apotexs propose generic product infringe merck nasonex formulation patent apotexs application approve fda enter market united states generic version nasonex agreement generic manufacturer launch generic version zetia united states december expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country table content agreement apotex inc apotex corp collectively apotex grant right merck nasonex use patent united states addition district court decision uphold appeal court appeal federal circuit find apotexs propose generic product infringe merck nasonex formulation patent apotexs application approve fda enter market united states generic version nasonex company anticipate sales nasonex united states decline significantly patent expiry generic entry addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty company follow key patent protection drug candidate review united states fda additional patent term provide pipeline candidate base patent term restoration pediatric exclusivity currently anticipate review year expiration corifollitropin alfa injection formulationuse sugammadex sodium injection vorapaxar timothy grass pollen allergen extract use short ragweed pollen allergen extract use hpv vaccine valent suvorexant september merck receive complete response letter crl fda resubmission new drug application sugammadex sodium injection address crl company conduct hypersensitivity study anticipate file new drug application resubmission fda june merck receive crl fda suvorexant february company resubmitte new drug application fda company follow key patent protection drug candidate phase development currently anticipate phase drug candidate year expiration inactivated varicella zoster virus vzv vaccine use pediatric hexavalent combination vaccine method makingvectors odanacatib vintafolide anacetrapib tildrakizumab composition mka actoxumabbezlotoxumab omarigliptin ertugliflozin note patent chart compound patent patent subject future patent term restoration year month pediatric market exclusivity available addition depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity compound patent estate united states data protection generally run table content year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity research development expense billion billion billion include restructuring cost year million million million inprocess research development impairment charge respectively company prioritize research development effort focus candidate believe represent breakthrough science difference patient payer increase emphasis externally source program company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologics capability merck move diversify portfolio collaboration development biosimilar potential harness market opportunity present biological medicine patent expiry deliver high quality biosimilar enhance access patient worldwide company commit make externally source program great component pipeline strategy renew focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company review pipeline examine candidate provide value outlicense company evaluate certain latestage clinical development platform technology asset determine outlicense sale potential january company enter agreement divest sirna therapeutics inc subsidiary relate rnai technology asset companys clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease insomnia neurodegenerative disease osteoporosis respiratory disease women health development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic molecule believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human table content favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase trial design twostage trial design consist phase proofofconcept stage phase doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency stage propose manufacturing facility undergo preapproval inspection production vaccine progress examine detail united states fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review pursuant prescription drug user fee act fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience review staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review primary method company use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound table content product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluates maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state outside united states company submit marketing application national regulatory authority example pharmaceutical medical devices agency japan health canada agencia nacional vigilancia brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline market approval time long regulatory authority require approval major market united states issuance certificate pharmaceutical product market initiate local review process research development update company currently candidate regulatory review united states internationally vorapaxar investigational antithrombotic medicine review fda ema merck seek approval vorapaxar reduction atherothrombotic event add standard care patient history heart attack history stroke transient ischemic attack january fdas cardiovascular renal drug advisory committee recommend approval vorapaxar fda bind committee guidance take advice consideration review investigational medicine company ninevalent hpv vaccine development help protect certain hpvrelate disease review fda incorporate antigen additional cancercause hpv type compare gardasil company anticipate submit maa ema half corifollitropin alfa injection investigational fertility treatment review fda control ovarian stimulation woman participate assist reproductive technology approve corifollitropin alfa sustain follicular stimulant use fertility treatment regimen united states mercks corifollitropin alfa currently approve market outside united states include grastek timothy grass pollen allergen extract investigational timothy grass pollen allergy immunotherapy tablet ait ragwitek short ragweed pollen allergen extract investigational ragweed pollen ait review fda grastek propose trade ragwitek propose trade investigational sublingual tablet design help treat underlying cause allergic rhinitis generate immune response help protect allergic patient effect trigger target allergen merck partner alkabello develop investigational sublingual allergy immunotherapy tablet timothy grass pollen ragweed pollen house dust mite north america december fdas allergenic product advisory committee positive discussion january advisory committee positive discussion fda bind committee guidance take advice consideration review investigational medicine merck expect fdas review complete half february company announce grastek receive regulatory approval canada suvorexant investigational insomnia medicine new class medicine call orexin receptor antagonist use patient difficulty fall stay asleep july company announce receive crl fda nda suvorexant crl fda advise merck efficacy suvorexant establish dose elderly nonelderly adult patient start dose patient available suvorexant approve dose appropriate patient dose welltolerate effective patient take concomitant moderate cypa inhibitor dose necessary addition fda determine safety datum support approval suvorexant february company resubmitte nda fda previously disclose fda approval separate scheduling table content determination drug enforcement administration require merck introduce suvorexant united states insomnia condition characterize difficulty fall asleep andor stay asleep company submit new drug application suvorexant health authority japan continue plan seek approval suvorexant country world sugammadex sodium injection investigational agent reversal neuromuscular blockade induce rocuronium vecuronium neuromuscular block agent neuromuscular blockade anesthesiology induce muscle relaxation surgery september merck announce receive crl fda resubmission nda sugammadex sodium injection fdas letter raise concern operational aspect hypersensitivity study agency request address crl company conduct hypersensitivity study anticipate file nda resubmission fda sugammadex sodium injection approve launch country outside united states market bridion vintafolide investigational cancer candidate review ema exclusive license agreement endocyte inc endocyte merck responsible development worldwide commercialization vintafolide oncology ema accept maa filing vintafolide endocyte investigational companion diagnostic imaging agent etarfolatide target treatment patient folatereceptor positive platinumresistant ovarian cancer combination pegylate liposomal doxorubicin vintafolide etarfolatide grant orphan drug status vintafolide phase development united states vaniprevir investigational oral twicedaily protease inhibitor treatment chronic hepatitis virus hcv infection review japan addition candidate regulatory review company drug candidate phase development target broad range disease company anticipate file nda bla applicable fda respect candidate investigational antipd immunotherapy currently evaluate treatment patient advance melanoma tumor type january company announce start roll submission fda bla patient advance melanoma previously treat ipilimumab roll submission allow complete portion application submit review fda ongoing basis company expect complete application half april merck announce receive breakthrough therapy designation advanced melanoma fda note designation investigational drug breakthrough therapy intend expedite development review candidate plan use combination treat lifethreatening disease condition preliminary clinical evidence indicate drug demonstrate substantial improvement exist therapy clinically significant endpoint clinical development program include study broad range cancer type include bladder colorectal gastric head neck melanoma nonsmall cell lung renal triple negative breast hematological malignancy addition company announce collaboration pharmaceutical company evaluate novel combination regimen odanacatib oral onceweekly investigational treatment patient osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis july merck announce update phase trial assess fracture risk reduction odanacatib independent datum monitor committee dmc study complete plan interim analysis efficacy recommend study close early robust efficacy favorable benefitrisk profile dmc note safety issue remain certain select area recommendation respect follow february merck announced recently receive review safety efficacy datum phase trial result review datum company conclude review additional datum previously plan ongoing extension study warrant filing application approval fda table content delay previously announce company conduct blinded extension trial approximately woman provide additional safety efficacy datum merck continue anticipate file application approval odanacatib additional data extension trial company continue believe odanacatib potential address unmet medical need patient osteoporosis investigational hexavalent pediatric combination vaccine contain component current vaccine design help protect potentially disease diphtheria tetanus whooping cough bordetella pertussis polio poliovirus type invasive disease cause haemophilus influenzae type hepatitis develop collaboration sanofipasteur company continue anticipate file bla fda anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigate lipid management raise hdlc reduce ldlc anacetrapib evaluate large eventdriven cardiovascular clinical outcome trial reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease predict complete merck novel investigational oral amyloid precursor protein sitecleave enzyme bace inhibitor treatment alzheimer disease evaluate phase clinical trial epoch design evaluate safety efficacy versus placebo patients mildto moderate alzheimer disease base positive dmc recommendation follow plan analysis interim safety datum include safety cohort patient treat month company recently begin enrol patient phase portion trial new phase trial apec design evaluate safety efficacy versus placebo patient amnestic mild cognitive impairment alzheimer disease know prodromal alzheimer disease mka actoxumabbezlotoxumab investigational candidate prevention clostridium difficile infection recurrence combination monoclonal antibody treat patient single infusion omarigliptin investigational onceweekly dipeptidyl peptidase dpp inhibitor development treatment type diabete ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabetes company enter worldwide japan collaboration agreement pfizer inc development commercialization ertugliflozin insulin glargine candidate treatment patient type type diabetes february company announce expand collaboration samsung bioepis develop manufacture commercialize term agreement company collaborate clinical development regulatory filing manufacture approve merck commercialize candidate inactivated vzv vaccine development prevention herpe zoster company conduct phase trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy tildrakizumab antiinterleukin monoclonal antibody candidate investigate treatment psoriasis mkmk alloral combination regimen phase development consist investigational hcv nsa protease inhibitor investigational hcv nsa replication complex inhibitor grant breakthrough therapy designation october fda treatment chronic hcv infection investigate broad clinical program include study patient multiple hcv genotype treatmentnave treatment failure important hcv subpopulation patient cirrhosis coinfecte hiv mka nomace market zoely investigational oral contraceptive use woman prevent pregnancy november merck receive crl fda nomace merck decision discontinue phase clinical trial nomace conduct united states decision base new safety efficacy finding table content company provide update clinical program preladenant merck investigational adenosine receptor antagonist treatment parkinson disease initial review data separate phase trial provide evidence efficacy preladenant compare placebo base result merck take step discontinue extension phase study long plan pursue regulatory filing preladenant decision discontinue study base safety find company record impairment charge million relate discontinuation clinical development program preladenant chart reflect company research pipeline february candidate show phase include specific product date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area additional claim line extension formulation inline product show phase phase phase entry date review allergy atherosclerosis allergy immunotherapy anacetrapib grass pollen alzheimer disease alzheimer disease ragweed december fertility asthma clostridium difficile infection corifollitropin alfa injection mka actoxumabbezlotoxumab hepatitis bacterial infection november vaniprevir japan diabete mellitus hpvrelate cancer cancer omarigliptin september hpv vaccine valent dalotuzumab ertugliflozin november insomnia february suvorexant cmv prophylaxis transplant patient herpe zoster neuromuscular blockade reversal letermovir inactivated vzv vaccine december sugammadex sodium injection contraception medicate ius melanoma august platinumresistant ovarian cancer contraception generation ring osteoporosis vintafolide mka odanacatib september thrombosis mkb pediatric hexavalent combination vaccine vorapaxar useu hepatitis april footnote platinumresistant ovarian cancer north american rights vintafolide april new nonproprietary review hiv psoriasis phase adaptive design doravirine tildrakizumab december january company announce start roll nonsmall cell lung cancer submission fda bla patients advanced melanoma previously treat ipilimumab pneumoconjugate vaccine june merck receive crl fda suvorexant february company resubmitte nda rheumatoid arthritis fda september merck receive crl fda resubmission nda sugammadex sodium injection address crl company conduct hypersensitivity study anticipate file nda resubmission fda employee december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide table content employee company represent collective bargaining group addition company joint venture china brazil include consolidated result merck employee restructure program october company announce new global restructuring program restructuring program global initiative sharpen commercial research development focus new program company expect reduce total workforce approximately position workforce reduction primarily come elimination position sale administrative headquarters organization research development company reduce global real estate footprint continue improve efficiency manufacture supply network company continue hire employee strategic growth area business necessary merger restructuring program subsequent merck scheringplough merger merger company commence action global restructuring program merger restructuring program design streamline cost structure combine company action program initiate action program primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility inception merger restructuring program december merck eliminate approximately position comprise employee separation elimination contractor vacant position approximately position elimination remain pende program old program december restructuring action merger restructuring program substantially complete end exception certain action principally manufacturingrelate subsequent merger company rationalize number manufacture site worldwide remain action program result additional manufacturing facility rationalization expect substantially complete environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million million million estimate million aggregate year amount consider potential recovery party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue total million december possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial position result operation liquidity capital resource year merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy water use greenhouse gas emission company believe risk material business time geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion table content operation abroad company closely review method operation adopt strategy responsive change economic political condition merck expand operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time financial information geographic area company business provide item financial statement supplementary datum available information company internet website address wwwmerckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutleadership information available print stockholder request company item risk factor investor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate new drug application fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate table content company patent potential legislation relate patent reform regulatory initiative result erosion intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available case certain product loss result material noncash impairment charge company result operation adversely affect lost sale company successfully launch commercially successful replacement product chart list patent protection company major market product set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company business cash flow result operation financial position prospect patent provide market exclusivity nasonex expire january company anticipate sale decline significantly court rule propose generic form nasonex apotex generic manufacturer infringe company patent nasonex apotex receive approval market united states generic form nasonex company experience loss nasonex sale addition september approve biosimilar remicade company experience generic competition certain small european market company anticipate substantial decline remicade sale follow loss market exclusivity major european market february key company product generate significant company profit cash flow event adversely affect market lead product material negative impact result operation cash flow company ability generate profit operate cash flow depend largely continue profitability company key product januvia zetia remicade gardasil janumet isentress vytorin nasonex result company dependence key product event adversely affect product market product significant impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postmarket trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale certain product event result material noncash impairment charge company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market table content decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result clinical trial new drug successful new drug effective harmful effect new drug approve fda intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication increase uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection merger acquisition company devote substantial resource development mercks antipd immunotherapy assurance approve marketing fda january company announce initiate rolling submission fda bla company antipd immunotherapy patient advance melanoma previously treat ipilimumab company state expect complete submission half assurance company complete submission fda approve marketing sale united states initial indication additional indication addition approve assurance succeed marketplace company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority table content united states include fda foreign regulatory authority include united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval include result postmarkete phase trial study decrease demand company product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market change government standard public expectation safety efficacy labeling change great scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pharmaceutical medical device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity company face intense competition low costgeneric product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection table content significantly weak united states united states political pressure reduce spending prescription drug lead legislation measure encourages use generic product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial position prospect company face intense competition competitor product addition factor certain circumstance lead noncash impairment charge company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial position prospect addition product measure fair value capitalize connection merger acquisition company portfolio product market treatment chronic hepatitis vytorin zetia experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product company face pricing pressure respect product company face increase pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition company face risk litigation government pricing calculation outside united states numerous major market include japan pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product company expect pricing pressure increase future health care industry united states continue subject increase regulation political action company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider congress state legislature major health care reform adopt law important market reform begin continue implementation new law expect expand access health care million americans end decade minimum rebate state participate medicaid program increase company brand prescription drug medicaid rebate extend medicaid manage care organization eligibility federal drug discount program table content extend rural referral center sole community hospital critical access hospital certain free stand cancer hospital certain additional children hospital addition law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole company require pay annual health care reform fee assess brand prescription drug manufacturer importer fee calculate base industry total sale brand prescription drug specify government program percentage manufacturer sale include determined tiere scale base manufacturers individual revenue manufacturers portion total annual fee base manufacturer proportion total includable sale prior year annual industry fee billion billion company predict likelihood future change health care industry general pharmaceutical industry particular impact company result operation financial condition business uncertainty global economic condition austerity measure take certain government negatively affect company operating result uncertainty global economic condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial position prospect global effort health care cost containment continue exert pressure product pricing market access international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action include biennial price reduction japan austerity measure continue negatively affect revenue performance company continue monitor credit economic condition greece spain italy portugal member economic condition inherent variability time cash receipt result continue result increase average length time take collect account receivable outstanding country impact likelihood collect outstanding account receivable december company account receivable greece italy spain portugal total approximately million hospital public sector receivables approximately million aggregate approximately relate greece italy spain portugal respectively december company total account receivable outstanding year approximately million approximately relate account receivable greece italy spain portugal comprise hospital public sector receivables credit economic condition europe worsen result economic currency impact affect market globally material adverse effect company result company significant global operation expose additional risk adverse event material negative impact company result operation extent company operation outside united states significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement foreign exchange fluctuation table content diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease company evaluate strategic option merck consumer care animal health business assurance transaction occur january company announce evaluate respective role merck animal health consumer care business company strategy longterm value creation furthermore company state expect complete evaluation process action company reach different decision business assurance company determine action respect business able effectuate action determine company experience difficulty delay manufacture certain product previously disclose merck past experienced difficulty manufacture certain vaccine product company future experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture construction delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply manufacturing difficulty result product shortage lead lose sale company face significant litigation relate vioxx september merck voluntarily withdraw vioxx arthritis acute pain medication market worldwide merck settle major portion product liability litigation company face material litigation arise voluntary withdrawal vioxx addition vioxx product liability lawsuit lawsuit certain state participate previouslydisclose settlement purport class action individual lawsuit bring merck current officer director merck allege merck false misleading statement vioxx violation federal security law state law suit refer vioxx security lawsuit vioxx security lawsuit transfer judicial panel multidistrict litigation district court district new jersey district judge stanley chesler inclusion nationwide multidistrict litigation consolidated purpose merck name defendant action country outside united states suit refer vioxx international lawsuit vioxx litigation discuss fully item financial statement supplementary datum note contingency environmental liability company believe meritorious defense vioxx product liability lawsuit vioxx security lawsuit vioxx international lawsuit collectively vioxx litigation vigorously defend company insurance coverage respect vioxx litigation adequate cover defense cost loss company currently able estimate additional amount require pay connection vioxx litigation proceeding expect continue year company predict course proceeding view inherent difficulty predict outcome litigation company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx litigation company establish material reserve potential liability relate remain vioxx litigation establish reserve relate table content settlement certain vioxx international lawsuit respect certain vioxx product liability lawsuit discuss item financial statement supplementary datum note contingency environmental liability unfavorable outcome vioxx litigation result payment substantial damage material adverse effect company business cash flow result operation financial position prospect issue concern vytorin enhance clinical trial adverse effect sale vytorin zetia united states result improveit trial material adverse effect sale company sell vytorin zetia previously disclose january company announce result enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease previously report despite fact ezetimibesimvastatin vytorin significantly lower ldl bad cholesterol simvastatin significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease improveit trial currently underway design provide cardiovascular outcome data ezetimibesimvastatin patient present acute coronary syndrome schedule completion later incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin establish improveit trial blind interim efficacy analysis conduct datum safety monitoring board dsmb trial approximately endpoint accrue respectively case dsmb recommend continue trial change design dsmb complete plan interim review study datum march recommend study continue issue concern enhance clinical trial adverse effect sale vytorin zetia continue adverse effect sale result improveit trial fail demonstrate incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin sale zetia vytorin materially adversely affect sale product materially adversely affect company business cash flow result operation financial position prospect materially adversely affect company require record material noncash impairment charge company able realize expect benefit investment emerge market company take step increase presence emerge market guarantee company effort expand sale emerge market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect instance february venezuelan government devalue currency result devaluation company recognize loss exchange venezuelan government devalue currency company recognize additional loss exchange company expect impact great addition china governmental investigation involve multinational pharmaceutical company domestic health care company medical institute adversely affect company near term growth prospect market company continue believe china represent important growth table content opportunity event couple heighten scrutiny health care industry continue impact product pricing market access generally company anticipate report inquiry governmental authority involve multinational pharmaceutical company china continue reason sale emerge market carry significant risk failure continue expand company business emerge market material adverse effect business financial condition result company operation company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect company result operation financial position cash flow occur venezuela order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful company subject evolve complex tax law result additional liability affect result operation company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue april president obamas administration repropose significant change international tax law include change tax company excess return attributable certain offshore intangible asset limit tax deduction expense relate unrepatriated foreignsource income modify foreign tax credit rule potentially significant change international law include territorial tax system tax currently accumulate unrepatriated foreign earning control foreign corporation set congressional committee company determine proposal enact law change proposal prior enact law change international tax law enact significant impact financial result company addition company affect change tax law include tax rate change change law relate remittance foreign earning deferral limitation impact tax treatment foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action change law regulation adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business table content reliance party relationship outsource arrangement adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure size complexity company computer system make potentially vulnerable service interruption malicious intrusion random attack addition datum privacy security breach employee pose risk datum include intellectual property personal information expose unauthorized individual public assurance company effort protect datum system prevent service interruption loss critical sensitive information result financial legal business reputational harm company negative event animal health industry negative impact future result operation future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact company result operation outbreak highly contagious disease near company main production site require company immediately halt production vaccine site force company incur substantial expense procure raw material vaccine risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment company business significant impact event future result operation significant company voluntarily suspend sale zilmax animal feed supplement united states canada concerns raise cattle fed zilmax suspension materially reduce sale zilmax company assurance sale zilmax united states canada resume biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction united states result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing table content procedure require human vaccine candidate fda approval require release manufacture commercial lot manufacture biologic especially large quantity complex require use innovative technology handle living micro organism lot approve biologic undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost increase significantly respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability legacy merck product sell date company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forward look statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability table content obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant litigation relate vioxx fosamax legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarters currently locate whitehouse station new jersey company announce intends headquarters kenilworth new jersey company commercial operation headquarter upper gwynedd pennsylvania company pharmaceutical business conduct divisional headquarters locate upper gwynedd whitehouse station company vaccine business conduct divisional headquarters locate west point pennsylvania mercks animal health consumer care global headquarters function locate summit new jersey company announce vacate summit property principal research facility locate rahway kenilworth summit new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facility outside united states locate netherlands switzerland china company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia table content capital expenditure billion billion billion united states amount million billion billion abroad expenditure amount million million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable executive officer registrant age february time merger november certain executive officer assume position newly merge company note kenneth frazi age december chairman president chief executive officer merck inc january president chief executive officer merck inc president merck inc responsible company large worldwide division global human health merck manufacturing division merck research laboratory prior frazi executive vice president president global human health merck inc adele ambrose age november senior vice president chief communication officer merck inc responsible global communication organization december vice president chief communication officer merck inc responsible global communication organization john canan age november senior vice president financeglobal controller merck inc responsible company global controller organization include accounting control external reporting financial standard policy january senior vice president controller merck inc responsible corporate controller group willie deese age november executive vice president president merck manufacturing division merck inc responsible company global manufacturing procurement distribution logistic function january executive vice president president merck manufacturing division merck inc responsible company global manufacturing procurement distribution logistic function table content richard deluca age september executive vice president president merck animal health merck inc responsible merck animal health organization prior september deluca chief financial officer becton dickinson bioscience medical technology company president wyeths fort dodge animal health division serve chief operating officer fort dodge executive vice president chief financial officer cuong viet age october executive vice president chief strategy officer merck inc responsible leading formulation execution company long term strategic plan prior october senior vice president corporate strategy business development connectivity global company design manufacture market product customer variety industry senior vice president chief strategy officer lenovo personal technology company clark golestani age december executive vice president chief information officer merck inc responsible mercks global information technology august vice president merck research laboratorie information technology merck inc responsible global mercks research development division include basic research preclinical clinical regulatory mirian graddickweir age november executive vice president human resource merck inc responsible global human resource organization january executive vice president human resource merck inc responsible global human resource organization bridgette heller age march executive vice president president merck consumer care merck inc responsible merck consumer care organization prior march heller president johnson johnsons global baby business unit michael holston age june executive vice president chief ethic compliance officer merck inc responsible company compliance function include global safety environment system assurance ethic privacy prior june holston executive vice president general counsel board secretary hewlettpackard company technology company oversaw legal compliance government affair privacy ethic operation peter kellogg age november executive vice president chief financial officer merck inc responsible company worldwide financial organization investor relation corporate development global facility company joint venture relationship august executive vice president chief financial officer merck inc responsible company worldwide financial organization investor relation corporate development licensing company joint venture relationship table content bruce kuhlik age november executive vice president general counsel merck inc responsible legal communication public policy function january executive vice president general counsel merck inc responsible legal communication public policy function roger perlmutter age april executive vice president president merck research laboratories merck inc responsible company research development effort worldwide prior april perlmutter executive vice president research development amgen inc michael rosenblatt age december executive vice president chief medical officer merck inc company primary voice global medical community critical issue patient safety oversight company global center scientific affair prior december rosenblatt dean tufts university school medicine adam schechter age executive vice president president global human health merck inc responsible company pharmaceutical vaccine worldwide business november president global human health marketintegration leader merck inc commercial responsibility united states company portfolio prescription medicine leader integration effort merckscheringplough merger division function august president global pharmaceuticals global human health merck inc global responsibility company atherosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchise commercial responsibility united states company portfolio prescription medicine february board accept resignation john canan retire company march elect rita karachun senior vice president finance global controller effective march make company principal accounting officer karachun age serve assistant controller company november prior appointment assistant controller company karachun serve assistant controller scheringplough corporation february responsible prepare financial statement worldwide consolidation international entity officer list serve pleasure board director officer elect pursuant arrangement understand officer board table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information cash dividend pay common share year common stock market price high low high low january approximately shareholder record issuer purchase equity security month end december follow issuer purchase equity security millions total number average price approximate dollar value share share pay purchase period purchase share plan programs october october november november december december total share purchase period plan approve board director purchase billion merck share include million share receive october settlement accelerate share repurchase agreement cash pay period table content performance graph follow graph assume investment december reinvestment dividend companys common share index composite peer group major usbased pharmaceutical company abbott laboratories bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer grp merck peer grp performance graph reflect scheringplough stock performance december close merger merck stock performance november december assume cash component merger consideration reinveste merck stock closing price november compound annual growth rate discuss november merck scheringplough complete merger merck subsequently rename merck sharp dohme corp msd whollyowne subsidiary scheringplough subsequently rename merck inc result merger msd long exist publicly trade entity cease trade common stock close business merger date msd permanently remove peer group index addition abbott laboratories abbott currently include peer group abbott spin pharmaceutical business abbvie inc future company intend remove abbott peer group calculation performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem solicit material file securities exchange commission subject regulation provide regulation liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report merck inc subsidiarie million share amount result year sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder cash dividend declare cash dividend declare common share capital expenditure depreciation average common share outstanding million average common share outstanding assume dilution million yearend position work capital property plant equipment net total asset longterm debt total equity yearend statistic number stockholder record number employee amount include amortization purchase accounting adjustment impact restructure action intangible asset impairment charge include inprocess research development impairment charge reflect research development expense favorable impact certain tax item amount include amortization purchase accounting adjustment net charge record connection settlement certain shareholder litigation inprocess research development impairment charge reflect research development expense impact restructuring action favorable impact certain tax item amount include amortization purchase accounting adjustment inprocess research development impairment charge reflect research development expense impact restructuring action arbitration settlement charge favorable impact certain tax item include net favorable impact approximately million relate settlement federal income tax audit amount include amortization purchase accounting adjustment inprocess research development impairment charge billion reflect research development expense impact restructuring action reserve relate vioxx litigation gain recognize astrazeneca lps exercise option acquire certain asset company favorable impact certain tax item amount include impact merger scheringplough corporation november include recognition gain represent fair value stepup merck previously hold interest merckscheringplough partnership result obtain control interest amortization purchase accounting adjustment record postmerger period include gain sale merck interest merial limited favorable impact certain tax item impact restructuring action reflect dividend declare merck common stock addition approximately million dividend pay subsequent merger scheringplough million pay prior merger relate common stock prefer stock dividend declare scheringplough number employee december reflect employee company joint venture china brazil include consolidated result merck table content item management discussion analysis financial condition result operation description merck business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel overview company revenue performance temper ongoing business challenge include recent product patent expiry ongoing global effort health care cost containment continue exert pressure product pricing market access worldwide sale billion decline compare include unfavorable effect foreign exchange decline drive primarily recent loss market exclusivity product particularly singulair medicine indicate chronic treatment asthma relief symptom allergic rhinitis maxalt product acute treatment migraine propecia product treatment male pattern hair loss temodar treatment certain type brain tumor company experience significant rapid decline sale product follow loss market exclusivity decline partially offset high sale vaccine immunology diabete hiv product company continue successfully execute cost reduction initiative marketing administrative expense research development cost billion combine basis compare reflect target reduction promotional spending low cost result portfolio prioritization effort drive companywide efficiency merck take strategic operating action response business challenge rapidly change external environment face design drive short longterm growth october company announce multiyear global initiative sharpen commercial research development focus design enable merck well allocate resource candidate believe capable provide unambiguous promotable advantage patient payer include bolster pipeline implement agile operating model significantly reduce flexible cost structure maintain high level cash return shareholder geographically company increase focus prioritize market account majority revenue pharmaceutical vaccine business markets united states japan france germany canada united kingdom china brazil russia korea company continue invest highgrowth key emerge market core human pharmaceutical vaccine business merck continue support inline portfolio prepare promise launch pipeline company increase focus key therapeutic area meet unmet medical need provide good opportunity business deliver great value customer diabete acute hospital care vaccine oncology intensify portfolio assessment process company divest portion ophthalmic business sell marketing right saphris table content antipsychotic indicate treatment schizophrenia bipolar disorder adult company portfolio assessment process ongoing future product divestiture occur addition january company announce evaluate respective role merck animal health consumer care business company strategy longterm value creation company expect complete evaluation process action company reach different decision business company refocus research development effort include program company antipd immunotherapy oncology receive breakthrough therapy designation food drug administration fda advance melanoma merck bace inhibitor alzheimer disease company oral combination regimen treatment chronic hepatitis virus infection mkmk ninevalent human papillomavirus hpv vaccine january company announce initiate rolling submission biologic license application bla fda patient advance melanoma previously treat ipilimumab company receive breakthrough therapy designation mkmk advanced combination phase diverse range chronic hepatitis patient company initiate phase trial bace inhibitor file bla fda merck pursue emerge product opportunity independent therapeutic area modality building biologic capability company expect externally source program great component pipeline strategy company enter collaboration agreement development commercialization ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabete phase clinical development company outlicense discontinuing select latestage clinical development asset reduce focus platform technology company outlicense investigational treatment certain type ovarian cancer january enter agreement divest sirna therapeutics inc subsidiary relate rnai technology asset company currently candidate review fda vorapaxar investigational antithrombotic medicine review european union ninevalent hpv vaccine corifollitropin alfa injection investigational fertility treatment grastek investigational timothy grass pollen allergy immunotherapy tablet ait ragwitek investigational ragweed pollen ait vintafolide investigational cancer candidate review vaniprevir investigational oral twicedaily protease inhibitor treatment chronic hepatitis virus infection review japan february company resubmitte new drug application nda fda suvorexant respond agencys complete response letter crl receive addition company anticipate resubmitte nda application fda sugammadex sodium injection medication reversal certain muscle relaxant surgery company receive crl research development company candidate phase development anticipate file new drug application nda bla applicable fda respect candidate include completion roll submission bla patient advance melanoma previously treat ipilimumab october connection implementation company new global initiative company announce global restructure program restructuring program program company expect reduce total workforce approximately position workforce reduction primarily come elimination position sale administrative headquarters organization research development company reduce global real estate footprint continue improve efficiency manufacture supply network company record total pretax cost billion related restructuring program action restructure program expect substantially complete end cumulative pretax cost estimate approximately billion billion company expect action restructure program result annual net cost saving approximately billion end company anticipate action restructure program combine remain action merger restructuring program discuss result annual net cost saving billion end compare fullyear expense level table content global restructuring program merger restructuring program initiate subsequent merck scheringplough corporation scheringplough merger merger intend streamline cost structure combine company workforce reduction associate plan relate elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company record total pretax cost billion million billion related restructuring program restructuring action merger restructuring program substantially complete end exception certain action principally manufacturingrelate subsequent merger company rationalize number manufacture site worldwide remain action program result additional manufacturing facility rationalization expect substantially complete company expect estimate total cumulative pretax cost program approximately billion billion yield annual saving completion program approximately billion billion cost associate company restructure action include material production cost market administrative expense research development expense restructure cost company estimate project cost associate mention restructure program approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company return billion cash shareholder stock buyback activity dividend payment pursuant billion share repurchase program approve merck board director merck enter accelerated share repurchase asr agreement goldman sachs goldman sachs asr merck repurchase million share common stock billion utilize funding underwritten public debt offering november mercks board director raise company quarterly dividend share share earning common share assume dilution attributable common shareholder ep compare eps year reflect net unfavorable impact result acquisitionrelate cost restructure cost certain item nongaap eps exclude item compare nongaap income nongaap eps decline nongaap eps compare primarily low sale reflect loss market exclusivity certain product particularly singulair low equity income high foreign exchange loss partially offset low operating expense eps benefit low average share outstanding asr program discuss competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug consumer animal health care manufacturer company operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect intangible asset associate certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system table content strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor company consumer care operation face competition consumer health care business retailer carry private label brand companys competitive position affect factor include regulatory legislative issue scientific technological advance quality price company product promotional effort growth low cost private label brand health care environment global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient backdrop united states enact major health care reform legislation began implement insurance market reform advance continue implementation law expect expand access health care million americans end decade previously insurance coverage respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual health care reform fee total annual industry fee billion billion fee assess company proportion share sale certain government program medicare medicaid company record million million million cost marketing administrative expense respectively annual health care reform fee impact health care reform predict time company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company effort health care cost containment remain intense european country country continue announce execute austerity measure include implementation pricing action table content reduce price generic patent drug mandatory switch generic drug company take step mitigate impact country austerity measure continue negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance addition majority country attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug brand authority use price data market set new local price brandname drug include company guideline examine reference pricing usually set local market change pursuant local regulation addition japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine furthermore government order repricing class drug determine appropriate applicable rule certain market outside united states implement cost management strategy health technology assessment require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement company focus share revenue emerge market increase government emerge market focus constrain health care cost enact price control relate measure compulsory license aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force government regulation pharmaceutical industry subject regulation regional country state local agency world governmental regulation legislation tend focus standard process determine drug safety effectiveness condition sale reimbursement especially relate pricing product particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy table content procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition company farreache philanthropic program merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccine merck announce launch merck mother longterm effort global health partner end preventable death complication pregnancy childbirth initiative merck leverage scientific business expertise help prove solution widely available develop new technology improve public policymaker awareness issue merck past provide fund merck foundation independent organization partner variety organization dedicate improve global health partnership african comprehensive hivaids partnership botswana collaboration government botswana renew support botswana response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy datum protection company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include recently enact law regulation united states europe asia latin america increase enforcement litigation activity united states develop market operating result sale worldwide sale total billion decline compare billion sale decline drive primarily low sale singulair patent provide market exclusivity market exclusivity number major european market singulair expire august february respectively company experience significant rapid decline singulair sale market foreign exchange unfavorably affect global sale performance revenue decline reflect low sale maxalt cozaar hyzaar treatments hypertension temodar clarinex nonsedate antihistamine pegintron treatment chronic hepatitis propecia fosamax treatment osteoporosis vytorin cholesterol modify medicine decline partially offset growth gardasil vaccine help prevent certain disease cause type hpv remicade simponi treatment inflammatory disease janumet treatment type diabete isentress treatment hiv infection dulera inhalation aerosol combination medicine treatment asthma zostavax vaccine help prevent shingles herpe zoster sales united states billion decline compare billion sale decrease drive primarily low sale singulair maxalt temodar victrelis oral medicine treatment chronic hepatitis virus clarinex partially offset high sale gardasil zetia cholesterol absorption inhibitor dulera inhalation aerosol international sale billion decline compare billion foreign exchange unfavorably affect international sale performance decline drive primarily low sale pharmaceutical segment reflect decline japan largely attributable unfavorable effect foreign exchange europe partially offset growth emerge market sale japan decline billion unfavorable effect foreign exchange sale decline table content reflect ongoing impact loss market exclusivity product include cozaar hyzaar low sale gardasil reflect japanese government decision suspend proactive recommendation hpv vaccine decline pegintron rebetol product treatment chronic hepatitis declines partially offset volume growth januvia treatment type diabete nasonex inhale nasal corticosteroid treatment nasal allergy symptom zetia rotateq vaccine help protect rotavirus gastroenteritis infant child sale europe decline billion include favorable effect foreign exchange drive ongoing generic erosion fiscal austerity measure region partially offset growth remicade simponi janumet januvia isentress sale emerge market grow billion include unfavorable effect foreign exchange reflect high sale vaccine hospital hepatitis immunology product partially offset low sale singulair diversified brand total international sale represent total sale respectively global effort health care cost containment continue exert pressure product pricing market access worldwide international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action include biennial price reduction japan austerity measure continue negatively affect revenue performance october company sell active pharmaceutical ingredient api manufacturing business effective december certain relate product diversified brand november merck sell right certain ophthalmic product january sell right saphris aggregate annual sale associate divest asset approximately million annual sale associate divest product approximately million approximately million related pharmaceutical segment million relate consumer care segment annual sale associate divest api manufacturing business approximately million relate nonsegment revenue worldwide sale billion decline compare billion foreign exchange unfavorably affect global sale performance sale decrease drive primarily singulair lose market exclusivity united states august result significant rapid decline singulair sale sale decline drive low sale remicade largely result arbitration settlement agreement reach discuss addition low sale cozaar hyzaar clarinex fosamax vytorin primaxin antibacterial product avelox broadspectrum fluoroquinolone antibiotic treatment certain respiratory skin infection low revenue company relationship astrazeneca azlp contribute sale decline decline largely offset high sale januvia gardasil victrelis zostavax janumet isentress zetia dulera inhalation aerosol high sale company animal health consumer care product table content sale company product follow primary care women health cardiovascular zetia vytorin diabete obesity januvia janumet respiratory nasonex singulair dulera asmanex womens health endocrine nuvare fosamax follistim implanon cerazette arcoxia avelox hospital specialty immunology remicade simponi infectious disease isentress cancida pegintron invanz victrelis noxafil oncology temodar emend cosopttrusopt bridion integrilin diversify brand cozaarhyzaar primaxin zocor propecia clarinex remeron claritin proscar maxalt vaccine gardasil proquadmmr iivarivax zostavax pneumovax rotateq pharmaceutical total pharmaceutical segment sale segment sale total segment sale amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health consumer care alliance alliance segment include revenue company relationship azlp revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result discuss october company divest substantial portion thirdparty manufacturing sale addition revenue reflect million revenue outlicense pipeline compound table content pharmaceutical segment primary care women health cardiovascular worldwide sale zetia market ezetrol outside united states cholesterol absorption inhibitor billion increase compare include unfavorable effect foreign exchange sale increase primarily reflect favorable pricing united states volume growth japan partially offset unfavorable effect foreign exchange particularly japan sales zetia increase billion include unfavorable effect foreign exchange sale increase reflect positive performance united states price volume growth japan partially offset volume decline united states global sale vytorin market outside united states inegy combination product contain active ingredient zetia zocor statin modify cholesterol billion decline compare drive primarily low volume united states latin america partially offset volume growth asia pacific region worldwide sales vytorin decline billion include unfavorable effect foreign exchange sale decline reflect volume decline united states partially offset pricing united states volume growth certain international market march datum safety monitoring board dsmb improveit trial large cardiovascular outcome study evaluate ezetimibesimvastatin simvastatin patient present acute coronary syndrome complete planned review study datum recommend study continue merck remain blind actual result analysis improveit safety efficacy datum improveit patient eventdriven trial base target number clinical endpoint rate event report trial project conclude later result improveit trial fail demonstrate incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin sale zetia vytorin materially adversely affect company non cash impairment charge respect carry value zetia vytorin intangible asset billion billion respectively december charge material diabetes obesity global sale januvia mercks dipeptidyl peptidase dpp inhibitor treatment type diabete billion decline compare include unfavorable effect foreign exchange exclude negative effect foreign exchange sale performance compare reflect volume growth japan positive performance europe emerge market partially offset decline united states reflect lower demand worldwide sale januvia rise billion compare reflect volume growth united states international market particularly japan foreign exchange unfavorably affect sale performance company anticipate dpp inhibitor include januvia subject reprice japan trial evaluate cardiovascular outcome treatment sitagliptin tecos eventdriven cardiovascular outcome study sitagliptin begin patient enrol tecos evaluate impact sitagliptin add usual care compare usual care sitagliptin large highrisk type diabete population multiple country tecos expect complete later worldwide sale janumet merck oral antihyperglycemic agent combine sitagliptin januvia metformin single tablet billion increase compare drive primarily volume growth outside united states global sale janumet billion increase compare reflect volume growth united states emerge market europe foreign exchange unfavorably affect sale performance global sale combine diabetes franchise januviajanumet billion increase compare include unfavorable effect foreign exchange billion increase compare include unfavorable effect foreign exchange table content respiratory global sale nasonex inhale nasal corticosteroid treatment nasal allergy symptom increase billion compare drive primarily increase united states reflect net favorable adjustment indirect customer discount volume growth japan partially offset decline latin america canada europe foreign exchange unfavorably affect global sale performance agreement generic manufacturer able launch generic version nasonex european market january generic version nasonex launch market accordingly company anticipate rapid decline nasonex sales europe sales nasonex europe million apotex inc apotex corp collectively apotex file application fda seek approval sell generic version nasonex june district court district new jersey rule company patent infringement suit apotex hold apotexs generic version nasonex infringe company formulation patent june court appeal federal circuit issue decision affirm district court decision company exhaust appeal option apotexs generic version available significant loss nasonex sale occur company noncash impairment charge respect carry value nasonex intangible asset billion december nasonex intangible asset determine impaired impairment charge material sale nasonex million worldwide sale nasonex decline billion include unfavorable impact foreign exchange sale performance compare reflect price decline europe low volumes united states largely offset high price united states worldwide sale singulair onceaday oral medicine chronic treatment asthma relief symptom allergic rhinitis fall billion compare drive primarily low sale united states europe result generic competition patent provide market exclusivity singulair expire august company lose nearly sale singulair united states addition patent provide market exclusivity singulair expire number major european market february company experience significant rapid reduction sale singulair market follow patent expiry expect decline continue patent provide market exclusivity singulair japan expire singulair sale japan million global sale singulair decline billion compare drive primarily low sale united states revenue decline europe canada latin america contribute singulair sale decline global sale dulera inhalation aerosol combination medicine treatment asthma million million million reflect high demand united states dulera inhalation aerosol approve fda june january merck receive crl fda company supplemental new drug application dulera inhalation aerosol treatment chronic obstructive pulmonary disease company determine conduct additional clinical study long pursue update application women health endocrine worldwide sale nuvare vaginal contraceptive product million increase compare primarily reflect volume growth favorable pricing united states global sale nuvare million comparable sale foreign exchange unfavorably affect sale performance exclude unfavorable impact foreign exchange sale performance reflect volume growth emerge market positive performance europe worldwide sale fosamax market fosamac japan fosamax plus market fosavance treatment case fosamax prevention osteoporosis decline million decrease million drive decline region medicine lose market exclusivity united states major international market company expect sale decline fosamax product franchise continue global sale follistim market country outside united states puregon fertility treatment grow million compare drive largely positive performance united states sale follistim decline million include unfavorable effect foreign table content exchange drive largely decline europe result supply issue price puregon lose market exclusivity august worldwide sale implanon singlerod subdermal contraceptive implant grow million compare drive primarily volume growth united states partially offset decline emerge market pricing pressure implanon sale increase million include unfavorable effect foreign exchange reflect volume growth emerge market united states recent year company experience difficulty manufacture certain women health product company resolve issue material company result operation product include primary care women health include asmanex twisthaler inhale corticosteroid asthma cerazette progestin oral contraceptive arcoxia treatment arthritis pain avelox broadspectrum fluroquinolone antibiotic treatment certain respiratory skin infection market company united states patent provide market exclusivity avelox expire march hospital specialty immunology sale remicade treatment inflammatory disease market company europe russia turkey billion increase compare include favorable effect foreign exchange sale growth reflect volume growth europe russia september approve infliximab biosimilar company experience generic competition certain small european market company anticipate substantial decline remicade sale follow loss market exclusivity major european market february sale remicade billion decline compare include unfavorable effect foreign exchange prior july remicade market company outside united states japan certain asian market result agreement reach april amend agreement govern distribution right remicade simponi effective july merck relinquish marketing right product certain territory include canada central south america middle east africa asia pacific merck retain exclusive marketing right europe russia turkey retain territory retain territory remicade sale decline reflect unfavorable effect foreign exchange volume growth europe sale simponi oncemonthly subcutaneous treatment certain inflammatory disease market company europe russia turkey million million million drive continued launch activity simponi approve european commission october september approve simponi treatment adult patient moderately severely active ulcerative colitis inadequate response conventional therapy intolerant medical contraindication therapie infectious disease worldwide sale isentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection grow billion compare drive primarily volume growth united states europe global sale isentress grow billion compare drive primarily volume growth united states latin america asia pacific region foreign exchange unfavorably affect global sale performance global sale cancidas antifungal product increase million compare reflect growth emerge market europe japan sales cancidas decline million reflect unfavorable effect foreign exchange growth emerge market worldwide sale pegintron treatment chronic hepatitis decline million compare reflect decline region company believe sale decline attributable patient treatment delay health care provider anticipation new therapeutic option available table content foreign exchange unfavorably affect global sale performance global sale pegintron decline million include unfavorable effect foreign exchange exclude unfavorable impact foreign exchange sale performance reflect volume growth favorable pricing united states volume growth certain emerge market global sale victrelis oral medicine treatment chronic hepatitis million decline compare include unfavorable effect foreign exchange sale decline united states europe canada partially offset growth emerge market company believe sale decline united states europe canada attributable patient treatment delay health care provider anticipation new therapeutic option available sale victrelis million compare million drive postlaunch growth united states internationally particularly europe victrelis approve fda july sale company product indicate treatment chronic hepatitis include victrelis pegintron discuss rebetol continue adversely affect patient treatment delay health care provider anticipation new therapeutic option available sale rebetol product sell entirely international market particularly adversely affect trend give market rebetol sell generic competition worldwide sale rebetol decline million drive decline japan europe cash flow revision fourth quarter indicate rebetol intangible asset value recoverable undiscounted cash flow basis utilize market participant assumption company conclude good estimate fair value intangible asset relate rebetol million december result impairment charge million record material production cost event availability new treatment option adversely affect sale product currently market company treatment chronic hepatitis great extent anticipate company event circumstance arise significantly reduce cash flow projection product company record additional intangible asset impairment charge future charge material carry value intangible asset relate product billion aggregate december oncology sale temodar market temodal outside united states treatment certain type brain tumor decline million compare foreign exchange unfavorably affect global sale performance sale decline drive primarily generic competition united states europe previously disclose agreement generic manufacturer launch generic version temodar united states august patent exclusivity period expire february temodar lose patent exclusivity accordingly company experience sale decline loss exclusivity market company expect decline continue sale temodar decrease million include unfavorable effect foreign exchange sale decline europe generic competition offset price increase united states global sales emend prevention chemotherapyinduce postoperative nausea vomit million increase compare include unfavorable effect foreign exchange largely reflect volume growth united states emerge market partially offset decline japan sale emend million increase compare include unfavorable effect foreign exchange reflect volume growth united states japan worldwide sale ophthalmic product cosopt trusopt million decline compare reflect unfavorable effect foreign exchange low sale europe canada generic competition partially offset volume growth japan patent cosopt expire number major european market march company experience sale decline market patent provide market exclusivity cosopt trusopt united states trusopt number major european market previously expire sale cosopt trusopt million decline compare include unfavorable effect foreign exchange sale decline primarily reflect low sale europe generic erosion price reduction mitigate high cosopt sale japan table content november merck sell right ophthalmic product cosopt cosopt azasite akorn inc annual sale associate ophthalmic product approximately million bridion sugammadex sodium injection reversal certain muscle relaxant surgery approve launch country outside united states sale bridion million increase compare sale growth drive volume growth europe emerge market japan partially offset unfavorable effect foreign exchange primarily sale japan sale bridion grow million drive primarily high sale japan emerge market september company receive crl fda resubmission nda sugammadex sodium injection research development saphris asenapine antipsychotic indicate treatment schizophrenia bipolar disorder adult previously market company united states merck sale saphris million million million asenapine sell brand sycrest approve treatment bipolar disorder adult commercialization agreement sycr sublingual tablet lundbeck lundbeck make product supply payment exchange exclusive commercial right sycr market outside united states china japan second quarter company reduce cash flow projection saphrissycrest result reduce expectation international markets united states revision cash flow indicate saphrissycr intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption consider different scenario determine good estimate fair value intangible asset relate saphrissycrest compare related carrying value result impairment charge million reflect material production cost january merck sell right saphris forest laboratories inc forest term agreement forest upfront payment approximately million additional payment merck base define sale milestone product contain hospital specialty include invanz treatment certain infection noxafil prevention certain invasive fungal infection integrilin treatment patient acute coronary syndrome sell company united states canada diversify brand mercks diversify brand include human health pharmaceutical product approach expiration marketing exclusivity long protect patent develop market continue core company offer market world global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension billion decline compare include unfavorable effect foreign exchange decline drive largely low sale japan europe canada generic competition unfavorable effect foreign exchange particularly sale japan sale cozaarhyzaar decrease billion drive decline region patent provide market exclusivity cozaar hyzaar united states number major international market expire accordingly company experience significant decline cozaar hyzaar sale company expect decline continue worldwide sale propecia product treatment male pattern hair loss million decline compare include unfavorable impact foreign exchange decline drive primarily generic competition united states low sale japan largely unfavorable effect foreign exchange company lose market exclusivity propecia multiple generic enter market accordingly company experience significant decline sale propecia expect decline continue sale propecia decline million compare drive decline europe united states partially offset increase asia pacific region global sale clarinex market aerius country outside united states nonsedate antihistamine decline million decrease million drive low volume united states europe result generic competition company anticipate sale clarinex continue decline table content global sale maxalt product acute treatment migraine fall million compare drive primarily low volume united states generic competition patent provide market exclusivity maxalt expire december company experience significant rapid decline maxalt sale addition patent provide market exclusivity maxalt expire number major european market august company experience sale decline market sale maxalt million comparable sale reflect high sale united states drive favorable pricing offset volume decline europe canada generic erosion product contain diversified brand include primaxin antibacterial product zocor statin modify cholesterol prescription claritin treatment seasonal outdoor allergy yearround indoor allergy remeron antidepressant proscar urology product treatment symptomatic benign prostate enlargement vaccine follow discussion vaccine include sale vaccine sell major european market sanofi pasteur msd spmsd company joint venture sanofi pasteur result reflect equity income affiliate select joint venture affiliate information supply sale spmsd include merck sale gardasil vaccine help prevent certain disease cause type hpv grow billion compare drive primarily volume growth united states reflect continued uptake male female volume growth latin america partially offset low volume japan sale include million million respectively purchase center disease control prevention cdc pediatric vaccine stockpile june japanese health ministry issue advisory suspend active promotion hpv vaccine accordingly company record sale gardasil japan second half merck sale gardasil rise billion compare drive primarily growth united states reflect continued uptake male high government purchase cdc pediatric vaccine stockpile growth emerge market particularly latin america asia pacific region japan company party certain thirdparty license agreement respect gardasil include crosslicense settlement agreement glaxosmithkline result agreement company pay royalty worldwide gardasil sale vary country include material production cost merck sale proquad pediatric combination vaccine help protect measle mump rubella varicella million million million sale proquad affect supply constraint proquad available united states order october merck sale varivax vaccine help prevent chickenpox varicella million million million merck sale mmr vaccine help protect measle mump rubella million million million sale varivax mmr decline availability proquad discuss merck sale zostavax vaccine help prevent shingles herpe zoster adult year age old million million million sale growth compare drive high demand united states canada launch asia pacific region company continue launch zostavax outside united states sales zostavax affect supply issue merck sale pneumovax vaccine help prevent pneumococcal disease grow million compare drive primarily volume growth emerge market volume price increase united states mercks sale pneumovax increase million primarily growth united states result price increase high volume partially offset decline japan mercks sale rotateq vaccine help protect rotavirus gastroenteritis infant child grow million compare reflect high pricing united states volume growth table content japan merck sale rotateq decline million reflect favorable public sector inventory fluctuation partially offset volume growth emerge market japan segment company segment animal health consumer care alliance segment material separate reporting january company announce evaluate respective role merck animal health consumer care business company strategy longterm value creation company expect complete evaluation process action company reach different decision business animal health animal health include pharmaceutical vaccine product prevention treatment control disease major farm companion animal species animal health sale affect competition frequent introduction generic product global sale animal health product billion decline compare include unfavorable effect foreign exchange sale decline reflect low sale ruminant product primarily zilmax partially offset growth companion animal poultry product august merck animal health voluntarily suspend sale zilmax feed supplement beef cattle united states canada suspension zilmax unfavorably affect animal health sale sale animal health product billion increase compare include unfavorable effect foreign exchange drive positive performance ruminant poultry companion animal swine product consumer care consumer care product include overthecounter foot care sun care product claritin nondrowsy antihistamine miralax relief occasional constipation scholl foot care product coppertone sun care product consumer care product sale affect competition consumer spending pattern global sale consumer care product billion decline compare include unfavorable effect foreign exchange sale decline result termination china certain consumer care distribution arrangement reversal sale previously distributor associate termination cost exclude item consumer care global sale increase compare include unfavorable effect foreign exchange reflect high sale women health product partially offset low sale foot care product company launch oxytrol woman overthecounter treatment overactive bladder woman consumer care product sale grow include unfavorable effect foreign exchange billion reflect high sale scholl coppertone miralax claritin partially offset low sale marvelon oral contraceptive overthecounter product china discuss december company divest certain product aspen annual sale product reflect consumer care approximately million alliance alliance segment include result company relationship azlp revenue azlp primarily relate sale nexium prilosec million million billion astrazeneca option buy merck interest subsidiary merck interest nexium prilosec exercisable company believe likely astrazeneca exercise option select joint venture affiliate information astrazeneca exercise option company long record equity income azlp supply sale azlp terminate addition company recognize noncash pretax gain approximately million table content cost expense million change change material production marketing administrative research development restructuring cost equity income affiliate income expense net great include million million million iprd impairment charge respectively material production material production cost billion billion billion cost include expense amortization intangible asset record connection merger acquisition total billion billion additionally expense include million amortization purchase accounting adjustment scheringplough inventory recognize result merger cost include intangible asset impairment charge million million respectively impairment charge relate change cash flow assumption currently mark product saphrissycrest rebetol pharmaceutical segment company recognize additional non cash impairment charge future relate product intangible measure fair value capitalize connection merger acquisition charge material additionally cost include million intangible asset impairment charge relate licensing agreement include material production cost associate restructuring activity amount million million million respectively include accelerate depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare amortization intangible asset purchase accounting adjustment inventory restructuring impairment charge note reduce gross margin percentage point percentage point percentage point exclude impact gross margin decline compare drive loss singulair sale result patent expiry united states august major european market february addition generic competition united states maxalt temodar clarinex propecia couple change product mix continue pricing pressure mature market negatively affect gross margin gross margin decline compare reflect significant decline singulair sale result loss market exclusivity partially offset improvement result change product mix company anticipate gross margin continue negatively affect ongoing impact recent patent expiry additional patent expiry occur market administrative marketing administrative expense decline billion decrease billion largely low promotional spending selling cost result restructuring activity reflect favorable effect foreign exchange expense include restructure cost million million million respectively relate primarily accelerate depreciation facility close divest separation cost associate sale force reduction incur reflect restructure cost discuss expense include million million million acquisitionrelate cost respectively consist incremental thirdparty integration cost relate merger include cost relate legal entity system integration acquisitionrelate cost consist severance cost associate acquisition inspire pharmaceuticals inc company formal restructuring program table content research development research development expense billion billion billion research development expense comprise cost directly incur merck research laboratory mrl company research development division focus human health relate activity approximately billion billion include research development expense cost incur division support research development activity include depreciation production general administrative licensing activity certain cost operate segment include pharmaceutical animal health consumer care segment aggregate billion billion billion respectively decline research development cost compare target reduction low clinical development spend result portfolio prioritization low payment license activity research development expense favorably affect cost saving result restructure activity research development expense include inprocess research development iprd impairment charge million million million respectively research development company recognize additional noncash impairment charge future cancellation delay pipeline program measure fair value capitalize connection merger acquisition charge material research development expense reflect million million million respectively accelerate depreciation asset abandonment cost associate restructuring activity company record adjustment accelerate depreciation cost include research development expense revise previously record amount certain facility restructuring cost restructure cost primarily represent separation relate cost associate restructuring activity billion million billion respectively cost include million cost relate restructuring program nearly remain cost record cost record related merger restructuring program separation cost billion million billion respectively incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate merck eliminate approximately position relate restructuring program relate merger restructuring program relate restructuring program approximately position relate merger restructuring program relate restructuring program relate legacy scheringplough program approximately position relate merger restructuring program relate restructuring program relate legacy scheringplough program position elimination comprise actual headcount reduction elimination contractor vacant position include restructuring cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan costs contract termination shutdown cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include material production marketing administrative research development discuss table content equity income affiliate equity income affiliate reflect performance company joint venture equity method affiliate decline million compare drive primarily low equity income azlp partially offset high equity income spmsd equity income affiliate increase million primarily high equity income azlp company divest interest johnson johnsonmerck consumer pharmaceutical company jjmcp joint venture select joint venture affiliate information income expense net income expense net million expense compare billion expense reflect million net charge relate settlement certain shareholder litigation enhance litigation note consolidated financial statement partially offset high exchange loss drive million exchange loss relate venezuelan currency devaluation note consolidated financial statement high interest expense result issuance debt september income expense net billion expense compare million expense reflect million net charge relate settlement enhance litigation gain recognize million disposition company interest jjmcp joint venture note consolidated financial statement million sale certain manufacturing facility relate asset note consolidated financial statement partially offset million charge relate resolution arbitration proceeding involve company right market remicade simponi high interest income segment profit million pharmaceutical segment profit nonreportable segment profit income income taxis segment profit comprise segment sale standard cost certain operating expense directly incur segment component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit amortization purchase accounting adjustment acquisitionrelate cost intangible asset impairment charge restructure cost taxis pay joint venture level portion equity income expense corporate manufacturing cost center miscellaneous income expense additionally segment profit reflect charge relate settlement enhance litigation record arbitration settlement charge gain divestiture company interest jjmcp joint venture gain sale certain manufacturing facility relate asset record unallocated item reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale divest product business supply sale pharmaceutical segment profit declined drive primarily effect loss market exclusivity certain product particularly singulair pharmaceutical segment profit increase drive primarily low operating expense offset effect loss market exclusivity singulair table content taxis income effective income tax rate reflect impact acquisitionrelate cost restructure cost partially offset beneficial impact foreign earning effective tax rate reflect net benefit million settlement certain federal income tax issue net benefit reduction tax reserve expiration applicable statute limitation favorable impact tax legislation enact quarter extend tax credit outofperiod net tax benefit approximately million associate resolution previously disclose legacy scheringplough federal income tax issue note consolidated financial statement effective tax rate reflect favorable impact tax settlement canada revenue agency cra realization foreign tax credit impact favorable rule state tax matter addition effective tax rate reflect unfavorable impact net charge record connection settlement enhance litigation tax benefit record reflect impact tax credit expire december result legislation pass extend tax credit tax credit recognize note effective tax rate reflect net favorable impact approximately million relate settlement merck federal income tax audit favorable impact certain foreign state tax rate change result net million reduction defer tax liability intangible establish purchase accounting unfavorable impact million charge relate resolution arbitration proceeding involve company right market remicade simponi net income earning common share net income attributable merck inc billion billion billion eps decline net income ep compare primarily low sale reflect loss market exclusivity certain product particularly singulair high restructuring cost intangible asset impairment charge exchange loss partially offset favorable impact certain tax item low operating expense eps benefit low average share outstanding asr program note consolidated financial statement decrease net income ep compare primarily net charge record connection settlement enhance litigation effect loss market exclusivity singulair favorable impact tax item partially offset low marketing administrative expense low restructuring cost low intangible asset impairment charge arbitration settlement charge record nongaap income nongaap ep nongaap income nongaap eps alternative view company performance management merck provide management believe information enhance investor understand company result nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consist acquisitionrelate cost restructure cost certain item exclude item significant component understand assess financial performance information nongaap income nongaap eps consider addition lieu net income ep prepared accordance generally accept accounting principle united states gaap additionally nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap income nongaap ep performance company measure basis performance metric senior management annual compensation derive nongaap income nongaap ep table content reconciliation gaap financial measure nongaap financial measure follow million share amount pretax income report gaap increase decrease exclude item acquisitionrelate cost restructure cost item net charge relate settlement enhance litigation arbitration settlement charge gain disposition interest jjmcp joint venture gain sale manufacturing facility relate asset taxis income report gaap estimate tax benefit exclude item net tax benefit settlement federal income tax issue tax benefit foreign state tax rate change nongaap net income net income attributable noncontrolle interest nongaap net income attributable merck inc eps assume dilution report gaap ep difference nongaap ep assume dilution represent difference calculate gaap ep calculate nongaap eps different calculate dividing impact exclude item weightedaverage share applicable year acquisitionrelate cost nongaap income nongaap eps exclude impact certain amount record connection merger acquisition amount include amortization intangible asset inventory stepup intangible asset impairment charge exclude incremental thirdparty integration cost associate merger cost relate legal entity system integration cost associate merger acquisition severance cost company formal restructuring program cost exclude management believe cost representative ongoing normal business activity restructure cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life site base anticipate date site close divest depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment shut relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation cost company undertake restructuring different type cover period charge consider nonrecurre management exclude amount nongaap income nongaap eps believe helpful understanding performance continue business certain item nongaap income nongaap eps exclude certain item item represent substantive unusual item evaluate individual basis evaluation consider quantitative qualitative aspect unusual nature generally represent item result nature magnitude management anticipate occur company normal business regular basis table content certain item comprise net charge record connection settlement enhance litigation arbitration settlement charge gain disposition company interest jjmcp joint venture gain associate sale certain manufacturing facility relate asset exclude nongaap income nongaap eps tax benefit resolution certain federal income tax issue research development chart reflect company current research pipeline february set forth item business research development research development update company currently candidate regulatory review united states internationally vorapaxar investigational antithrombotic medicine review fda european medicines agency ema merck seek approval vorapaxar reduction atherothrombotic event add standard care patient history heart attack history stroke transient ischemic attack january fdas cardiovascular renal drug advisory committee recommend approval vorapaxar fda bind committee guidance take advice consideration review investigational medicine company ninevalent hpv vaccine development help protect certain hpvrelate disease review fda incorporate antigen additional cancercause hpv type compare gardasil company anticipate submit marketing authorization application maa ema half corifollitropin alfa injection investigational fertility treatment review fda control ovarian stimulation woman participate assist reproductive technology approve corifollitropin alfa sustain follicular stimulant use fertility treatment regimen united states mercks corifollitropin alfa currently approve market outside united states include grastek investigational timothy grass pollen allergy immunotherapy tablet ait ragwitek investigational ragweed pollen ait review fda investigational sublingual tablet design help treat underlying cause allergic rhinitis generate immune response help protect allergic patient effect trigger target allergen merck partner alkabello develop investigational sublingual allergy immunotherapy tablet timothy grass pollen ragweed pollen house dust mite north america december fdas allergenic product advisory committee positive discussion january advisory committee positive discussion fda bind committee guidance take advice consideration review investigational medicine merck expect fdas review complete half february company announce grastek receive regulatory approval canada suvorexant investigational insomnia medicine new class medicine call orexin receptor antagonist use patient difficulty fall stay asleep july company announce receive crl fda nda suvorexant crl fda advise merck efficacy suvorexant establish dose elderly nonelderly adult patient start dose patient available suvorexant approve dose appropriate patient dose welltolerate effective patient take concomitant moderate cypa inhibitor dose necessary addition fda determine safety datum support approval suvorexant february company resubmitte nda fda previously disclose fda approval separate scheduling determination drug enforcement administration require merck introduce suvorexant united states insomnia condition characterize difficulty fall asleep andor stay asleep company submit new drug application suvorexant health authority japan continue plan seek approval suvorexant country world table content sugammadex sodium injection investigational agent reversal neuromuscular blockade induce rocuronium vecuronium neuromuscular block agent neuromuscular blockade anesthesiology induce muscle relaxation surgery september merck announce receive crl fda resubmission nda sugammadex sodium injection fdas letter raise concern operational aspect hypersensitivity study agency request address crl company conduct hypersensitivity study anticipate file nda resubmission fda sugammadex sodium injection approve launch country outside united states market bridion vintafolide investigational cancer candidate review ema exclusive license agreement endocyte inc endocyte merck responsible development worldwide commercialization vintafolide oncology ema accept maa filing vintafolide endocyte investigational companion diagnostic imaging agent etarfolatide target treatment patient folatereceptor positive platinumresistant ovarian cancer combination pegylate liposomal doxorubicin vintafolide etarfolatide grant orphan drug status vintafolide phase development united states vaniprevir investigational oral twicedaily protease inhibitor treatment chronic hepatitis virus infection review japan addition candidate regulatory review company drug candidate phase development target broad range disease company anticipate file nda bla applicable fda respect candidate investigational antipd immunotherapy currently evaluate treatment patient advance melanoma tumor type january company announce start roll submission fda bla patient advance melanoma previously treat ipilimumab roll submission allow complete portion application submit review fda ongoing basis company expect complete application half april merck announce receive breakthrough therapy designation advanced melanoma fda designation investigational drug breakthrough therapy intend expedite development review candidate plan use combination treat lifethreatening disease condition preliminary clinical evidence indicate drug demonstrate substantial improvement exist therapy clinically significant endpoint clinical development program include study broad range cancer type include bladder colorectal gastric head neck melanoma nonsmall cell lung renal triple negative breast hematological malignancy addition company announce collaboration pharmaceutical company evaluate novel combination regimen odanacatib oral onceweekly investigational treatment patient osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis july merck announce update phase trial assess fracture risk reduction odanacatib independent datum monitor committee dmc study complete plan interim analysis efficacy recommend study close early robust efficacy favorable benefitrisk profile dmc note safety issue remain certain select area recommendation respect follow february merck announced recently receive review safety efficacy datum phase trial result review datum company conclude review additional datum previously plan ongoing extension study warrant filing application approval fda delay previously announce company conduct blinded extension trial approximately woman provide additional safety efficacy datum merck continue anticipate file application approval odanacatib additional data extension trial company continue believe odanacatib potential address unmet medical need patient osteoporosis table content investigational hexavalent pediatric combination vaccine contain component current vaccine design help protect potentially disease diphtheria tetanus whooping cough bordetella pertussis polio poliovirus type invasive disease cause haemophilus influenzae type hepatitis develop collaboration sanofipasteur company continue anticipate file bla fda anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigate lipid management raise hdlc reduce ldlc anacetrapib evaluate large eventdriven cardiovascular clinical outcome trial reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease predict complete merck novel investigational oral amyloid precursor protein sitecleave enzyme bace inhibitor treatment alzheimer disease evaluate phase clinical trial epoch design evaluate safety efficacy versus placebo patients mildto moderate alzheimer disease base positive dmc recommendation follow plan analysis interim safety datum include safety cohort patient treat month company recently begin enrol patient phase portion trial new phase trial apec design evaluate safety efficacy versus placebo patient amnestic mild cognitive impairment alzheimer disease know prodromal alzheimer disease mka actoxumabbezlotoxumab investigational candidate prevention clostridium difficile infection recurrence combination monoclonal antibody treat patient single infusion omarigliptin investigational onceweekly dpp inhibitor development treatment type diabete ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabetes company enter worldwide japan collaboration agreement pfizer inc pfizer development commercialization ertugliflozin discuss insulin glargine candidate treatment patient type type diabetes february company announce expand collaboration samsung bioepis develop manufacture commercialize term agreement company collaborate clinical development regulatory filing manufacture approve merck commercialize candidate inactivated varicella zoster virus vaccine development prevention herpe zoster company conduct phase trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy tildrakizumab antiinterleukin monoclonal antibody candidate investigate treatment psoriasis mkmk alloral combination regimen phase development consist investigational hepatitis virus nsa protease inhibitor investigational hepatitis virus nsa replication complex inhibitor grant breakthrough therapy designation october fda treatment chronic hepatitis virus infection investigate broad clinical program include study patient multiple hepatitis virus genotype treatmentnave treatment failure important hepatitis virus subpopulation patient cirrhosis coinfecte hiv mka nomace market zoely investigational oral contraceptive use woman prevent pregnancy november merck receive crl fda nomace merck decision discontinue phase clinical trial nomace conduct united states decision base new safety efficacy finding company provide update clinical program preladenant merck investigational adenosine receptor antagonist treatment parkinson disease initial review datum table content separate phase trial provide evidence efficacy preladenant compare placebo base result merck take step discontinue extension phase study long plan pursue regulatory filing preladenant decision discontinue study base safety find company record impairment charge million relate discontinuation clinical development program preladenant company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologics capability merck move diversify portfolio collaboration development biosimilar potential harness market opportunity present biological medicine patent expiry deliver high quality biosimilar enhance access patient worldwide company commit make externally source program great component pipeline strategy renew focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company review pipeline examine candidate provide value outlicense company evaluate certain latestage clinical development platform technology asset determine outlicense sale potential company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease insomnia neurodegenerative disease osteoporosis respiratory disease women health inprocess research development connection merger acquisition company record fair value incomplete research project time acquisition reach technological feasibility december balance iprd billion significant project latestage development include vorapaxar companys bace inhibitor sugammadex sodium injection ait program discuss approximately million million million respectively iprd project receive marketing approval major market company begin amortize asset base estimate useful life iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development company realize future cash flow estimate record iprd acquisition date company recover research development expenditure acquisition develop program circumstance occur company future operating result adversely affect company recognize impairment charge charge material company record million iprd impairment charge research development expense million relate writeoff intangible asset associate preladenant result discontinuation clinical development program compound addition company record impairment charge result change cash flow assumption certain compound pipeline program previously deprioritize subsequently deem alternative use period company record million iprd impairment charge primarily pipeline program previously deprioritize subsequently deem alternative use period company record million iprd impairment charge primarily table content pipeline program abandon determined alternative use expect delay launch timing change cash flow assumption certain compound addition impairment charge relate pipeline program previously deprioritize deem alternative use period outlicense party consideration related asset carry value additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval december estimate cost complete project acquire connection merger acquisition phase development human health analogous stage development animal health approximately billion acquisition divestiture research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth company complete transaction broad range therapeutic category merck actively monitor landscape growth opportunity meet company strategic criterion april merck pfizer announce enter worldwide japan collaboration agreement development commercialization pfizer ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabetes company initiate phase clinical trial ertugliflozin pfizer term agreement merck pfizer collaborate clinical development commercialization ertugliflozin ertugliflozincontaine fixeddose combination metformin januvia sitagliptin tablets merck continue retain right exist portfolio sitagliptincontaine product end merck record research development expense million upfront milestone payment pfizer pfizer eligible additional payment associate achievement prespecifie future clinical regulatory commercial milestone company share potential revenue certain cost merck pfizer party certain manufacturing supply obligation company pfizer right terminate agreement material uncured breach insolvency party event safety issue pfizer right terminate agreement month notice time follow anniversary commercial sale collaboration product assign right ertugliflozin merck termination agreement depend circumstance party vary right obligation respect continued development commercialization ertugliflozin certain payment obligation september merck astrazeneca announce worldwide outlicense agreement merck oral small molecule inhibitor wee kinase currently evaluate phase clinical study combination standardofcare therapie treatment patient certain type ovarian cancer term agreement astrazeneca pay merck million upfront fee company record revenue addition merck eligible receive future payment tie development regulatory milestone plus salesrelated payment tiere royalty astrazeneca responsible future clinical development manufacturing marketing january company enter agreement divest sirna therapeutics inc subsidiary relate rnai technology asset alnylam pharmaceuticals inc alnylam term agreement consideration pay alnylam merck consist million cash share alnylam common stock value approximately million time agreement addition merck eligible receive million developmental sale milestone payment singledigit royalty associate certain preclinical candidate transaction subject customary closing condition expect close quarter table content select joint venture affiliate information expand research base realize synergy combine capability opportunity asset previous year merck form number joint venture astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale kbi product revenue million million billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership agreement preferential return represent merck share undistribute azlp gaap earning variable return relate companys limited partner interest return aggregate million million million respectively astrazeneca option purchase merck interest kbi base value merck interest nexium prilosec astrazenecas option exercisable march april astrazeneca choose exercise option closing date expect june amend agreement astrazeneca payment merck closing million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june exercise price include additional equal multiple time merck average annual profit allocation partnership year prior exercise company believe likely astrazeneca exercise option astrazeneca exercise option company long record equity income azlp supply sale azlp terminate addition company recognize noncash pretax gain approximately million sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe table content sale joint venture product follow million gardasil influenza vaccine viral vaccines zostavax rotateq hepatitis vaccine vaccine johnson johnsonmerck consumer pharmaceutical company merck sell interest jjmcp joint venture venture merck form develop manufacture market distribute certain overthecounter consumer product united states canada merck receive onetime payment million recognize pretax gain million reflect income expense net partnership asset include manufacture facility sale product market joint venture million period january september divestiture date capital expenditure capital expenditure billion billion billion expenditure united states million billion billion depreciation expense billion billion billion billion billion billion respectively apply location united states total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fully fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt cash provide operating activity billion billion billion cash provide operating activity include payment company million connection previously disclose settlement enhance litigation note consolidated financial statement cash provide operating activity reflect high contribution define benefit plan compare cash provide operating activity include payment million relate resolution certain litigation relate vioxx cash provide operating activity include million payment result arbitration settlement net payment approximately million internal revenue service result conclusion examination certain merck federal income tax return cash provide operating activity continue company primary source fund finance operating need capital expenditure treasury stock purchase dividend pay shareholder global economic condition ongoing sovereign debt issue factor adversely affect foreign receivables certain european country note consolidated financial statement company receive significant collection successful completing factoring arrangement portion receivable additionally company continue expand emerge market payment term tend long condition emerge market result increase table content average length time take collect account receivable outstanding adversely affect cash provide operating activity cash investing activity billion compare billion primarily reflect high proceed sale security investment low capital expenditure partially offset high purchase security investment cash investing activity billion compare billion primarily reflect high purchase security investment partially offset high proceed sale security investment cash financing activity billion compare billion high use cash financing activity drive primarily high purchase treasury stock largely asr agreement discuss high payment debt decrease short term borrowing partially offset high proceed issuance debt cash financing activity billion compare billion low use cash financing activity primarily drive proceed issuance debt low payment debt high proceed exercise stock option partially offset increase purchase treasury stock decrease shortterm borrowing high dividend pay stockholder december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment generally cash investment hold foreign subsidiary subject significant tax payment cash investment repatriate form dividend company record defer tax liability certain unremitte earning amount earn overseas expect indefinitely reinveste outside united states accrual taxis provide cash investment hold foreign subsidiary fluctuate variety factor include time receipt payment normal course business cash provide operating activity united states continue company primary source fund finance domestic operating need capital expenditure portion treasury stock purchase dividend pay shareholder company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation unrecognize tax benefit operating lease include future bulk supply purchase company commit connection certain divestiture include disposition api manufacturing business discuss december company consolidated balance sheet reflect liability unrecognize tax benefit interest penalty billion include million reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising amount reflect research development obligation include contingent milestone payment exclude research development obligation potential future funding commitment approximately million investment research venture capital fund loan payable current portion longterm debt reflect million longdate note subject repayment option holder require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million million respectively pension plan postretirement benefit plan table content company billion fiveyear credit facility mature facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility company complete underwritten public offer billion senior unsecured note consist billion aggregate principal note million aggregate principal float rate note billion aggregate principal note billion aggregate principal float rate note billion aggregate principal note billion aggregate principal note interest note payable semiannually note series redeemable time company option vary redemption price substantial portion net proceed note repurchase company common stock pursuant accelerated share repurchase agreement discuss december company file security registration statement security exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company longterm credit rating assign moodys investor service standard poor stable outlook stable outlook respectively rating continue allow access capital market flexibility obtain fund competitive term company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer despite strong financial profile certain contingent event realize discuss note consolidated financial statement material adverse impact company liquidity capital resource company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november board director declare quarterly dividend share company common stock payable january company announce board director authorize additional purchase billion merck common stock treasury company expect repurchase approximately billion common stock month follow date announcement finance combination debt issuance operating cash flow remainder repurchase time time limit purchase open market transaction block transaction exchange privately negotiate transaction company purchase billion common stock million share treasury include share asr agreement discuss company approximately billion remain share repurchase program company purchase billion billion common stock respectively previously authorize share repurchase program merck enter asr agreement goldman sachs asr merck agree purchase billion merck common stock total initial delivery approximately million share merck common stock base current market price goldman sachs merck payment billion merck goldman sachs settlement asr october merck receive additional million share determine average daily volume weightedaverage price merck common stock term asr program bring total share receive merck program million asr enter pursuant share repurchase program announce table content financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenues earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow weak dollar result net benefit market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign exchange option pricing model hold factor exchange rate constant merck principally use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow table content primary objective balance sheet risk management program mitigate exposure foreign currency denominate net monetary asset foreign subsidiary dollar functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly strengthen currency exposure company december income taxis decline approximately million company net long position relative major foreign currency consideration forward contract uniform strengthen dollar yield large overall potential net loss earning exchange december company net short position relative major foreign currency consideration forward contract uniform weaken dollar reduce income taxis approximately million measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow february venezuelan government devalue currency bolvar fuerte vef dollar vef dollar company recognize loss exchange approximately million result remeasurement local monetary asset liability new rate january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation march venezuelan government announce creation new foreign exchange mechanism call complimentary system foreign currency acquirement know sicad operate similar auction system allow entity specific sector bid dollar specify import transaction december regulation create sicad auction mechanism amend require central bank venezuela include website weekly average exchange rate imply transaction settle sicad auction mechanism week december bsf dollar company sicad auction mechanism settle transaction sicad mechanism describe auction attribute inconsistent free market auction accordingly company believe appropriate use sicad rate remeasurement gaap company continue monitor sicad auction mechanism possible circumstance change sicad mechanism take attribute true free market auction sicad rate utilize remeasurement purpose occur devaluation official rate occur result material charge company future result operation company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment comprehensive income oci remain accumulated comprehensive income aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment table content foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk company enter payfloate receivedfixed interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap mature notional amount million effectively convert company fixedrate note floatingrate instrument swap mature notional amount million effectively convert company fixedrate note floatingrate instrument swap mature notional million notional amount million notional million effectively convert company fix rate note floatingrate instrument swap mature notional amount million notional million effectively convert portion company note float rate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow interest rate swap outstanding december company terminate payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap effectively convert certain fixedrate note floatingrate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate result swap termination company receive million cash include million accrue interest correspond million basis adjustment debt associate terminate interest rate swap contract defer amortize reduction interest expense respective term note cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting policy company consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include initial fair value determination asset liability primarily iprd intangible asset subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent table content estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement merger acquisition business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date merger acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record fair value intangible asset include acquire iprd determine utilize information available near merger acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck separate determination useful life asset begin amortization judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue table content record net time value money discount customer collection account receivable expect excess year provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesaler contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision summarize information change aggregate indirect customer discount accrual follow millions balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return table content inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation table content environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan net periodic benefit cost pension postretirement benefit plan total million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december discount rate company pension postretirement benefit plan range compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset reference information company develop forward look return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return range compare range pension postretirement benefit plan company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline table content actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component aoci expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize market relate value asset ratably fiveyear period net loss amount aoci excess certain threshold amortize net periodic benefit cost average remain service life employee restructure cost restructure cost record connection restructuring program design reduce cost structure increase efficiency enhance competitiveness result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect material production cost market administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business purchase assign reporting unit company test goodwill impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macro economic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price additionally company evaluate extent fair value exceed carry value reporting unit date valuation perform company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible exclude iprd record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent table content carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company test iprd impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value iprd intangible asset carrying company conclude likely fair value carrying quantitative test compare fair value iprd intangible asset carrying value perform impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize company operate result impairment investment company review investment impairment base determination decline market value investment carrying value otherthantemporary company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthan temporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci taxis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operates estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income table content taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forward look statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder consolidate statement comprehensive income merck inc subsidiary year end december million net income attributable merck inc comprehensive income loss net taxis net unrealized gain loss derivative net reclassification net unrealized loss gain investment net reclassification benefit plan net gain loss prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck inc accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account exclude account receivable classified asset note inventory exclude inventory classified asset note defer income taxis current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc comprehensive income net tax cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net tax cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive income net tax cash dividend declare common stock share treasury stock share purchase supera joint venture formation net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization intangible asset impairment charge gain disposition interest equity method investment equity income affiliate dividend distribution equity affiliate defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment proceed sale security investment proceed sale interest equity method investment acquisition business net cash acquire disposition business net cash divest cash inflow outflow net investment hedge net cash investing activity cash flow financing activity net change shortterm borrowing payment debt proceed issuance debt purchase treasury stock dividend pay stockholder dividend pay proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis merger acquisition business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date merger acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record table content foreign currency translation account include accumulate comprehensive income loss aoci reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost market cost substantial majority domestic pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstout fifo method inventory consist currently market product certain product await regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt equity security classify availableforsale report fair value fair value company investment determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax comprehensive income oci decline fair value equity security consider thantemporary impairment loss charge income expense net company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci realize gain loss debt equity security include income expense net revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year accrual chargeback reflect direct reduction account receivable accrual rebate record current liability accrue balance relative provision chargeback rebate include account receivable accrue current liability million billion respectively december million billion respectively december company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion table content advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion respectively software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development capitalize software cost include property plant equipment amortize begin software project substantially complete asset ready intend use capitalize software cost associate project amortize year include company ongoing multiyear implementation enterprisewide resource planning system million million december respectively capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business purchase goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform base company recent annual impairment test complete october company conclude goodwill impair acquire intangible acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note company periodically evaluate current fact circumstance indicate carry value acquire intangible recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow inprocess research development inprocess research development iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination useful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company test iprd impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value iprd intangible asset carrying company conclude likely fair value carrying quantitative test compare fair value iprd intangible asset carrying value perform fair value carrying impairment loss recognize operating result research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize amortize shorter remaining license product patent life amount collaborative partner relate development activity generally reflect reduction research development expense specific milestone achieve nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost iprd impairment charge period table content sharebase compensation company expense sharebased payment employee requisite service period base grantdate fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income consolidate statement income use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include initial fair value determination asset liability primarily iprd intangible asset subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently adopt accounting standard quarter company adopt guidance issue financial accounting standard board fasb simplifie entity test indefinitelive intangible impairment amend guidance allow company assess qualitative factor determine morelikelythannot indefinitelive intangible asset impair basis determine necessary perform quantitative impairment test adoption guidance impact companys financial position result operation table content restructure restructuring program october company announce new global restructuring program restructuring program global initiative sharpen commercial research development focus new program company expect reduce total workforce approximately position workforce reduction primarily come elimination position sale administrative headquarters organization research development company reduce global real estate footprint continue improve efficiency manufacture supply network company continue hire employee strategic growth area business necessary company record total pretax cost billion related restructuring program action restructure program expect substantially complete end cumulative pretax cost estimate approximately billion billion company estimate approximately twothird cumulative pretax cost result cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest merger restructuring program subsequent merck scheringplough corporation scheringplough merger merger company commence action global restructuring program merger restructuring program design streamline cost structure combine company action program initiate action program primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility october company sell active pharmaceutical ingredient api manufacturing business include related manufacturing facility netherland aspen holding aspen plan manufacturing facility rationalization merger restructuring program conjunction sale party enter strategic longterm supply agreement aspen supply api company approximately employee support api business transfer merck aspen connection sale aspen acquire certain brand product merck transfer aspen effective december consideration transaction include cash million note receivable present value million time disposition note receivable consist million note present value million million note present value million payable year begin december cash portion consideration company receive million fourth quarter remain million receive company january december record receivable deferred income taxis current asset consolidate balance sheet conjunction transaction company transfer inventory million property plant equipment million cash million aspen reduce goodwill million intangible asset million asset million record million transactionrelated liability transaction result loss million record restructuring cost table content company record total pretax cost billion million billion related restructuring program inception merger restructuring program december merck record total pretax accumulate cost approximately billion eliminate approximately position comprise employee separation elimination contractor vacant position approximately position elimination remain pende program december include remain action restructure program report merger restructuring program discuss restructuring action merger restructuring program substantially complete end exception certain action principally manufacturingrelate subsequent merger company rationalize number manufacture site worldwide remain action program result additional manufacturing facility rationalization expect substantially complete company expect estimate total cumulative pretax cost program approximately billion billion company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divested restructuring program october merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness pretax cost million million million record respectively relate restructuring program inception restructuring program june merck record total pretax accumulate cost billion eliminate approximately position comprise employee separation elimination contractor vacant position restructure program substantially complete exception certain manufacturingrelated action expect complete july remain accrue liability future separation restructure program transfer merger restructuring program remain activity restructuring program account merger restructure program segment report restructuring charge unallocated expense table content follow table summarize charge related restructuring program activity type cost separation accelerate year end december cost depreciation total restructuring program material production marketing administrative research development restructuring cost merger restructuring program material production marketing administrative research development restructuring cost restructure program material production marketing administrative restructuring cost year end december merger restructuring program material production marketing administrative research development restructuring cost restructure program material production marketing administrative restructuring cost year end december merger restructuring program material production marketing administrative research development restructuring cost restructure program material production research development restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate approximately position eliminate restructure program position eliminate merger restructuring program approximately position eliminate restructure program approximately position elimination comprise actual headcount reduction elimination contractor vacant position accelerate depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life site base anticipated date table content site close divest depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck require accelerate depreciation site asset record impairment charge anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include million million million respectively asset abandonment shutdown relate cost additionally activity include certain employeerelate cost associate pension postretirement benefit plan note share base compensation activity reflect net pretax loss gain result sale facility relate asset million primarily reflect loss transaction aspen discuss million million adjustment record amount material period follow table summarize charge spend relate restructuring activity program separation accelerate cost depreciation total restructuring program restructuring reserve january expense payment receipt net noncash activity restructure reserve december merger restructuring program restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december restructure program restructure reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december cash outlay associate restructuring program expect substantially complete end cash outlay associate merger restructuring program substantially complete end exception certain action principally manufacturingrelate expect substantially complete legacy scheringplough program prior merger scheringplough commence productivity transformation program design reduce avoid cost increase productivity company record million accelerate depreciation cost include material production cost program substantially complete end table content acquisition divestiture research collaboration license agreement company continue strategy establish external alliance complement substantial internal research capability include research collaboration license preclinical clinical compound technology platform drive near longterm growth company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound arrangement include upfront payment royalty profit share payment contingent occurrence certain future event link success asset development expense reimbursement payment party september merck astrazeneca announce worldwide outlicense agreement merck oral small molecule inhibitor wee kinase currently evaluate phase clinical study combination standardofcare therapie treatment patient certain type ovarian cancer term agreement astrazeneca pay merck million upfront fee company record revenue addition merck eligible receive future payment tie development regulatory milestone plus salesrelated payment tiere royalty astrazeneca responsible future clinical development manufacturing marketing april merck pfizer inc pfizer announce enter worldwide japan collaboration agreement development commercialization pfizer ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabetes company initiate phase clinical trial ertugliflozin pfizer term agreement merck pfizer collaborate clinical development commercialization ertugliflozin ertugliflozincontaine fixeddose combination metformin januvia sitagliptin tablets merck continue retain right exist portfolio sitagliptincontaine product end merck record research development expense million upfront milestone payment pfizer pfizer eligible additional payment associate achievement prespecifie future clinical regulatory commercial milestone company share potential revenue certain cost merck pfizer party certain manufacturing supply obligation company pfizer right terminate agreement material uncured breach insolvency party event safety issue pfizer right terminate agreement month notice time follow anniversary commercial sale collaboration product assign right ertugliflozin merck termination agreement depend circumstance party vary right obligation respect continued development commercialization ertugliflozin certain payment obligation february merck supera farma laboratorio supera brazilian pharmaceutical company coowne cristlia eurofarma establish previously announce joint venture market distribute sell portfolio pharmaceutical brand generic product merck cristlia eurofarma brazil merck own joint venture cristlia eurofarma collectively transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value result merck recognize intangible asset currently market product million iprd million goodwill million defer tax liability million company record increase noncontrolle interest paidin capital amount million million respectively transaction close february accordingly result operation acquire business include company result operation begin date fourth quarter result change cash flow assumption certain compound company record million impairment charge relate iprd record supera transaction october merck aicuris enter exclusive licensing agreement provide merck worldwide right develop commercialize candidate aicuris novel portfolio investigational medicine target human cytomegalovirus hcmv include letermovir oral latestage antiviral candidate investigate treatment prevention hcmv infection transplant recipient aicuris receive upfront payment million approximately million company record research development expense eligible milestone payment million base successful achievement development regulatory commercialization goal hcmv candidate include letermovir additional table content backup candidate phase candidate design act alternate mechanism addition aicuris entitle receive royalty payment reflect advanced stage clinical program potential product result agreement merck responsible development activity cost agreement terminate party event material uncured breach insolvency agreement terminate merck time event compound license aicuris develop adverse safety profile material adverse issue arise related development efficacy dose regimen compound andor event certain patent invalid andor unenforceable certain jurisdiction merck terminate agreement respect certain compound successful completion proof concept clinical trial terminate agreement respect certain compound merck fails minimally invest compound addition merck terminate agreement time month prior write notice time completion phase clinical trial compound aicuris terminate agreement event merck challenge aicuris patent covering compound license aicuris termination agreement depend circumstance party vary right obligation respect continued development commercialization compound case termination cause merck certain royalty obligation april company enter agreement endocyte inc endocyte develop commercialize endocyte novel investigational therapeutic candidate vintafolide vintafolide currently evaluate phase clinical trial folatereceptor positive platinumresistant ovarian cancer proceed phase trial nonsmall cell lung cancer agreement merck gain worldwide right develop commercialize vintafolide endocyte receive million upfront payment company record research development expense eligible milestone payment million base successful achievement development regulatory commercialization goal vintafolide total cancer indication addition vintafolide receive regulatory approval merck endocyte share equally profit loss united states endocyte receive royalty sale product rest world endocyte retain right copromote vintafolide merck united states merck exclusive right promote vintafolide rest world endocyte responsible majority funding completion proceed trial merck responsible development activity development cost decision right vintafolide merck right terminate agreement day notice merck endocyte right terminate agreement material breach insolvency party endocyte right terminate agreement event merck challenge endocyte patent right relate vintafolide termination agreement depend circumstance party vary right obligation respect continued development commercialization vintafolide case termination cause merck certain royalty obligation profit loss sharing merck complete acquisition inspire pharmaceuticals inc inspire specialty pharmaceutical company focus develop commercialize ophthalmic product term merger agreement merck acquire outstanding share common stock inspire price share cash total approximately million transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption connection acquisition substantially purchase price allocate inspire product product right intangible asset relate deferred tax liability defer tax asset relate inspire net operating loss carryforward goodwill november merck sell right certain ophthalmic product akorn inc include azasite acquire inspire transaction march company sell merck biomanufacture network provider contract manufacturing development service biopharmaceutical industry wholly own merck fujifilm corporation fujifilm term agreement fujifilm purchase equity interest merck subsidiary own asset merck biomanufacture network comprise facility locate research triangle park north carolina billingham united kingdom agreement fujifilm merck commit purchase certain development manufacturing service fair value fujifilm threeyear period follow closing transaction transaction result gain million reflect income expense net table content remicadesimponi subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company exclusive marketing right product europe russia turkey december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system october european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi european union follow receipt pricing reimbursement approval profit derive merck exclusive distribution product equally divide merck april connection agreement merck amend agreement govern distribution right remicade simponi receive onetime payment merck million company record charge income expense net financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow table content connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge effective portion unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize hedge relationship highly effective hedge ineffectiveness minimis derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose primary objective balance sheet risk management program mitigate exposure foreign currency denominate net monetary asset foreign subsidiary dollar functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year table content company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci include cumulative translation adjustment pretax loss million million pretax gain million eurodenominate note interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk company enter payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap mature notional amount million effectively convert company fixedrate note floatingrate instrument swap mature notional amount million effectively convert company fixedrate note floatingrate instrument swap mature notional million notional amount million notional million effectively convert company fix rate note floatingrate instrument swap mature notional amount million notional million effectively convert portion company note float rate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow interest rate swap outstanding december company terminate payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap effectively convert certain fixedrate note floatingrate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate result swap termination company receive million cash include million accrue interest correspond million basis adjustment debt associate terminate interest rate swap contract defer amortize reduction interest expense respective term note cash flow contract report operating activity consolidate statement cash flow table content present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative derivative dollar dollar balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument interest rate swap contract non current asset interest rate swap contract non current noncurrent liability foreign exchange contract current defer income taxis current asset foreign exchange contract non current asset foreign exchange contract current accrue current liability derivative designate hedge instrument foreign exchange contract current defer income taxis current asset foreign exchange contract non current asset foreign exchange contract current accrue current liability table content note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross subject offset master netting arrangement offset consolidated balance sheet cash collateral receive post net amount table provide information location pretax gain loss amount derivative designate fair value hedge relationship designate foreign currency cash flow hedging relationship iii designate foreign currency net investment hedge relationship designate hedge relationship year end december derivative designate fair value hedge relationship interest rate swap contract loss gain recognize income expense net derivative gain loss recognize income expense net hedge item derivative designate foreign currency cash flow hedging relationship foreign exchange contract loss reclassify aoci sale gain loss recognize oci derivative derivative designate foreign currency net investment hedging relationship foreign exchange contract gain recognize income expense net derivative gain loss recognize oci derivative derivative designate hedge relationship foreign exchange contract loss gain recognize income expense net derivative loss recognize sale million ineffectiveness hedge ineffectiveness hedge represent exclude hedge effectiveness testing derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate december company estimate million pretax net unrealize gain derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information availableforsale investment december follow gross unrealized gross unrealize fair amortize fair amortize value cost gain loss value cost gain loss corporate note bond assetbacke security government agency security commercial paper mortgagebacke security foreign government bond equity security availableforsale debt security include shortterm investment total billion december remain debt security billion mature year december debt security pledge collateral fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset investment corporate note bond assetbacke security government agency security commercial paper mortgagebacke security foreign government bond equity security asset security hold employee compensation derivative asset purchase currency option forward exchange contract interest rate swap total asset liability derivative liability forward exchange contract write currency option interest rate swap total liability primarily assetbacke security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily credit card auto loan home equity receivables weightedaverage live primarily year mortgagebacked security represent aaarate security issue unconditionally guarantee payment principal interest government agency fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant transfer level level december cash cash equivalent billion include billion cash equivalent consider level fair value hierarchy company liability relate contingent consideration consider level fair value hierarchy associate business combination fair value million million december respectively fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy table content concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline approximately onethird company cash cash equivalent invest highly rate money market fund majority company account receivable arise product sale united states europe primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor economic condition include volatility associate international sovereign economy associate impact financial market business take consideration global economic condition ongoing sovereign debt issue certain european country company continue monitor credit economic condition greece italy spain portugal member economic condition inherent variability time cash receipt result continue result increase average length time take collect account receivable outstanding time value money discount record customer collection account receivable expect excess year december asset include million million respectively account receivable expect collect year company expect writeoff adjustment account receivable material adverse effect financial position liquidity result operation december company account receivable greece italy spain portugal total approximately million hospital public sector receivables approximately million aggregate approximately relate greece italy spain portugal respectively december company total account receivable outstanding year approximately million approximately relate account receivable greece italy spain portugal comprise hospital public sector receivables company complete nonrecourse factoring approximately million hospital public sector receivables spain company collect approximately million account receivable connection spanish government debt stabilizationstimulus plan addition company complete nonrecourse factoring approximately million hospital public sector account receivable italy additionally company continue expand emerge market payment term market tend long result increase account receivable balance certain market company customer large account receivable balance amerisourcebergen corporation cardinal health inc mckesson corporation zuellig pharma ltd asia pacific alliance healthcare represent aggregate approximately onefourth total account receivable december company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty december company receive cash collateral million million respectively counterpartie obligation return collateral record accrue current liability company advanced cash collateral counterpartie december table content inventory inventory december consist finished good raw material work process supply total approximate current cost increase lifo cost recognize inventory asset inventory value lifo method comprise approximately billion billion inventory december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch goodwill intangible follow table summarize goodwill activity segment pharmaceutical total goodwill balance january goodwill balance december acquisition divestiture goodwill balance december include cumulative translation adjustment goodwill balance certain adjustment addition pharmaceutical segment goodwill result formation supera joint venture note reduction result divestiture company api manufacturing business relate brand product note july company acquire remain share physician interactive provider online mobile clinical resource solution health care professional merck exist ownership interest million november merck acquire health management resource corporation leader medical weight management million transaction collectively result addition approximately million goodwill include segment pro forma financial information include transaction historical financial result significant compare company financial result table content intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right inprocess research development tradename acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life company significant acquire intangible relate market product december include zetia billion vytorin billion nasonex billion claritin billion nuvare million billion aggregate relate product market treatment chronic hepatitis victrelis pegintron rebetol company record impairment charge relate market product million million respectively material production cost record million result low cash flow projection saphrissycrest reduce expectation international markets united states revision cash flow indicate saphrissycr intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption consider different scenario determine good estimate fair value intangible asset relate saphrissycrest compare related carrying value result impairment charge note remain million impairment charge result low cash flow projection rebetol reduce expectation japan europe revision cash flow indicate rebetol intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate rebetol compare related carrying value result impairment charge note iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project company separate determination useful life asset begin amortization million million million respectively iprd reclassify product product right receipt marketing approval major market company record million iprd impairment charge research development expense million relate writeoff intangible asset associate preladenant result discontinuation clinical development program compound addition company record impairment charge result change cash flow assumption certain compound pipeline program previously deprioritize subsequently deem alternative use period company record million iprd impairment charge primarily pipeline program previously deprioritize subsequently deem alternative use period company record million iprd impairment charge primarily pipeline program abandon determined alternative use expect delay launch timing change cash flow assumption certain compound addition impairment charge relate pipeline program previously deprioritize deem alternative use period license party consideration related asset carry value table content iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense primarily record material production cost billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate comprise follow year end december astrazeneca primarily reflect result sanofi pasteur msd johnson johnsonmerck consumer pharmaceutical company dispose september astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale kbi product revenue million million billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate reflect table return include priority return provide partnership agreement preferential return represent merck share undistribute azlp gaap earning variable return relate companys limited partner interest astrazeneca option purchase merck interest kbi base value merck interest nexium prilosec astrazenecas option exercisable march april astrazeneca choose exercise option closing date expect june amend agreement astrazeneca payment merck closing million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june exercise price include additional equal table content multiple time merck average annual profit allocation partnership year prior exercise company believe likely astrazeneca exercise option summarize financial information azlp follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability merck partnership return azlp generally contractually determine note base percentage income azlp respect mercks limited partnership interest sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale billion billion billion johnson johnsonmerck consumer pharmaceutical company merck sell interest johnson johnsonmerck consumer pharmaceutical company jjmcp joint venture venture merck form develop manufacture market distribute certain overthecounter consumer product united states canada merck receive onetime payment million recognize pretax gain million reflect income expense net partnership asset include manufacture facility sale product market joint venture million period january september divestiture date investment affiliate account equity method include joint venture total billion december billion december amount report asset amount joint venture include defer income taxis current asset million december million december summarize information affiliate exclude azlp disclose separately follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability noncurrent liability include information jjmcp joint venture divestiture september table content loan payable longterm debt commitment loan payable december include billion note billion commercial paper million shortterm foreign borrowing million longdate note subject repayment option holder loan payable december include billion note billion commercial paper million shortterm foreign borrowing million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing december respectively longterm debt december consist note note note note note note note note note note floatingrate borrow note note note note note floatingrate borrow debenture note debenture note debenture eurodenominate note present table include million million december respectively borrowing variable rate average include foreign borrowing million million december respectively vary rate respectively exception debenture note list table redeemable merck option time vary redemption price company complete underwritten public offer billion senior unsecured note consist billion aggregate principal note million aggregate principal float rate note billion aggregate principal note billion aggregate principal float rate note billion aggregate principal note billion aggregate principal note interest note payable semiannually note series redeemable time company option vary redemption price substantial portion net proceed note repurchase company common stock pursuant accelerated share repurchase agreement note table content effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date certain company borrowing require merck comply financial covenant include requirement total debt capitalization ratio define applicable agreement exceed december company compliance covenant aggregate maturity longterm debt year follow billion billion billion billion billion company enter billion fiveyear credit facility mature facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility rental expense operating lease net sublease income million million million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action environmental matter vioxx litigation define separate assessment provide note opinion company unlikely resolution matter material company financial position result operation cash flow give nature litigation discuss include vioxx litigation complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august vioxx litigation product liability lawsuit previously disclose merck defendant approximately federal state lawsuit vioxx product liability lawsuit allege personal injury economic loss result purchase use vioxx remain case coordinate multidistrict litigation district court eastern district louisiana vioxx mdl judge eldon fallon merck reach resolution approve judge fallon remain federal court putative class action bring behalf individual purchaser user vioxx seek reimbursement allege economic loss settlement merck pay million pay properly document claim submit table content class member approve attorney fee expense approve settlement notice cost certain administrative expense court enter order approve settlement january period member submit claim settlement pende merck settle missouri state court class action plaintiff seek reimbursement outofpocket cost relate vioxx company establish reserve million connection settlement agreement minimum company require pay agreement settlement approve final judgment action enter courtapproved process class member submit claim settlement close october indiana plaintiff file motion certify class indiana vioxx purchaser case pende circuit court marion county indiana case dormant year april kentucky state court deny merck motion summary judgment certify class kentucky plaintiff seek reimbursement outofpocket cost relate vioxx trial court subsequently enter amend class certification order january matter settle namedplaintiffonly basis december merck defendant lawsuit bring state attorney general state alaska mississippi montana utah action pende vioxx mdl proceeding action allege merck misrepresented safety vioxx suit seek recovery expenditure vioxx governmentfunde health care program medicaid andor penalty allege consumer fraud act violation november circuit court franklin county kentucky approve settlement action file kentucky attorney general merck agree pay kentucky million resolve lawsuit relate appeal shareholder lawsuit previously disclose addition vioxx product liability lawsuit putative class action individual lawsuit federal security law state law file merck current officer director vioxx security lawsuit vioxx security lawsuit coordinate multidistrict litigation district court district new jersey judge stanley chesler consolidated purpose august judge chesler grant deny merck motion dismiss fifth amend class action complaint consolidate security action thing claim base statement voluntary withdrawal vioxx september dismiss october defendant answer fifth amend class action complaint april plaintiff file motion class certification january judge chesler grant motion march plaintiff file motion leave amend complaint add certain allegation expand class period court deny plaintiff motion leave amend complaint expand class period grant plaintiff leave amend complaint add certain allegation exist class period june plaintiff file sixth amend class action complaint july defendant answer sixth amend class action complaint discovery complete closed court scheduling order dispositive motion file january previously disclose individual security lawsuit file foreign institutional investor consolidate vioxx security lawsuit october plaintiff file amend complaint pende individual security lawsuit october new individual security lawsuit kbc lawsuit file district new jersey foreign institutional investor case consolidate vioxx security lawsuit january defendant file motion dismiss individual lawsuit abp lawsuit briefing motion dismiss complete march august judge chesler grant deny motion dismiss abp lawsuit thing certain allege misstatement omission dismiss inactionable state law claim dismiss september defendant answer complaint individual action kbc lawsuit day defendant move dismiss complaint kbc lawsuit statute limitation ground december judge chesler deny motion dismiss kbc lawsuit january defendant answer complaint kbc lawsuit discovery complete closed court scheduling order dispositive motion file january table content insurance company director officer insurance coverage applicable vioxx security lawsuit remain state upper limit approximately million currently partially fund company legal fee result previously disclose insurance arbitration additional insurance coverage claim available need upperlevel excess policy provide coverage variety risk dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state upper limit international lawsuit previously disclose addition lawsuit discuss merck name defendant litigation relate vioxx brazil canada europe israel collectively vioxx international lawsuit previously disclose company enter agreement resolve claim relate vioxx canada pursuant company pay minimum approximately million aggregate maximum approximately million agreement approve court canadas province reserve company believe meritorious defense remain vioxx product liability lawsuit vioxx security lawsuit vioxx international lawsuit collectively vioxx litigation vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx litigation company establish reserve respect canadian settlement certain vioxx product liability lawsuit immaterial settlement relate certain vioxx international lawsuit company immaterial remain reserve relate previously disclose vioxx investigation nonparticipating state litigation continue company establish liability reserve respect vioxx litigation unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation product liability litigation fosamax previously disclose merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case include approximately plaintiff group file pende merck federal state court include case seek class action certification damage andor medical monitoring approximately action plaintiff allege thing suffer osteonecrosis jaw onj generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax addition plaintiff approximately action generally allege sustained femur fracture andor bone injury femur fracture association use fosamax december merck reach agreement principle plaintiff steer committee fosamax onj mdl define resolve pende onj case appeal fosamax onj mdl state court aggregate million company record liability fourth quarter plaintiff counsel advise company intend participate settlement plan condition settlement state federal onj plaintiff agree participate settlement plan march participation achieve merck determine terminate agreement waive participation requirement agree less funding settlement fund tentative settlement effect case allege femur fracture discuss case allege onj andor jaw relate injury august judicial panel multidistrict litigation jpml order certain fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation table content fosamax onj mdl coordinated pretrial proceeding fosamax onj mdl transferred judge john keenan district court southern district new york result jpml order approximately case judge keenan fosamax onj mdl trial boles merck fosamax onj mdl court declare mistrial person jury reach unanimous verdict bole case retry june result verdict favor plaintiff million merck file posttrial motion seek judgment matter law alternative new trial october court deny merck posttrial motion sua sponte order remittitur reduce verdict million plaintiff reject remittitur order court request new trial damage plaintiff merck subsequently enter confidential stipulation plaintiff damage enable merck appeal underlie judgment merck file appeal bole case october prior case try verdict fosamax onj mdl defense verdict favor merck return case plaintiff file appeal case grave merck secrest merck january court appeal second circuit affirm judgment merck favor secrest plaintiff secrest case subsequently file petition writ certiorari supreme court deny june february judge keenan order bellwether trial conduct fosamax onj mdl spano merck jellema merck select court try case dismiss plaintiff march court select scheinberg merck case try trial scheinberg case begin january february jury return mixed verdict find favor merck plaintiff design defect claim find favor plaintiff failure warn claim award thousand compensatory damage merck posttrial motion judgment matter law scheinberg case deny july company file appeal court appeal second circuit november judge keenan issue order require plaintiff allege certain type specific injury provide expert report support claim deadline submission report stagger half date claim approximately plaintiff subject order dismiss prejudice august judge keenan deny merck request extend order additional group plaintiff decide start wind fosamax onj mdl remandtransfer remain case proper venue rate case month begin november date subsequently change plaintiff request december later suspend indefinitely addition july application atlantic county superior court new jersey request fosamax case pende new jersey consider mass tort designation centralize management judge new jersey october new jersey supreme court order pende future action file new jersey arise use fosamax seeking damage exist dental jawrelate injury include onj solely seek medical monitoring designate mass tort centralize management purpose judge carol higbee atlantic county superior court december approximately onj case pende merck atlantic county new jersey july judge higbee enter case management order amendment thereto set forth schedule contemplate complete fact expert discovery initial group case review trial february jury rosenberg merck trial new jersey coordinated proceeding return verdict merck favor april jury sessner merck second case try new jersey return verdict merck favor plaintiff file appeal case march new jersey appellate division affirm judgment merck favor rosenberg case case allege femur fracture march merck submit motion transfer jpml seek federal case allege femur fracture consolidate multidistrict litigation coordinate pretrial proceeding motion transfer grant federal case involve allegation femur fracture transfer multidistrict litigation district new jersey fosamax femur fracture mdl result jpml order approximately case pende fosamax femur fracture mdl december case management order enter require party review case later reduce case judge joel pisano select case group try initial bellwether case fosamax femur fracture mdl bellwether case glynn merck begin april jury return verdict merck table content favor april addition june judge pisano grant merck motion judgment matter law glynn case hold plaintiff failure warn claim preempt federal law judge pisano set trial date bellwether trial case allege injury take place january follow completion fact discovery court select sweet merck fosamax femur fracture mdl case try plaintiff subsequently dismiss case result trial date withdraw court expect set october trial date bellwether trial fosamax femur fracture mdl addition judge pisano enter order august require plaintiff fosamax femur fracture mdl cause case assert claim femur fracture injury take place prior september dismiss base court preemption decision glynn case plaintiff file response cause order end september merck file reply response end october hearing cause order hold january final rule court pende december approximately case allege femur fracture file new jersey state court pending judge higbee atlantic county superior court party select initial group case review fact discovery trial new jersey state femur fracture case merck begin early march mistrial declare later march plaintiff suffer medical issue unrelated use fosamax prevent proceed trial trial unanski merck set try begin november continue set trial potentially case love merck caravello merck beginning march additional group case review fact discovery select november december approximately case allege femur fracture file california state court petition file seek coordinate femur fracture case file california state court single judge orange county california petition grant judge steven perk preside coordinate proceeding november court order fact discovery commence party expect select round case include bellwether discovery pool additionally seven femur fracture case pende state court discovery ongoing fosamax femur fracture mdl state court femur fracture case pende company intend defend lawsuit januviajanumet previously disclose merck defendant product liability lawsuit unite states involve januvia andor janumet december approximately case serve pende merck alleging generally use januvia andor janumet cause development pancreatic cancer complaint file different state federal court claim pende consolidated multidistrict litigation proceed district court southern district california call incretinbase therapy product liability litigation proceeding include federal lawsuit allege pancreatic cancer use follow medicine januvia janumet byetta victoza product manufacture pharmaceutical company addition case note company agree december toll statute limitation additional claim company intend defend lawsuit nuvare previously disclose beginning number complaint file jurisdiction assert claim company subsidiarie organon usa inc organon pharmaceuticals usa inc organon international collectively organon company arise organon marketing sale nuvare nuvare litigation combine hormonal contraceptive vaginal ring plaintiff contend organon schering plough thing fail adequately design manufacture nuvare fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case currently pende federal multidistrict litigation nuvaring mdl venue missouri coordinated proceed new jersey state court table content december approximately file nuvare case approximately unfiled claim identify response census order issue nuvare mdl new jersey proceeding file case approximately pende nuvare mdl district court eastern district missouri judge rodney sippel approximately pende coordinated proceeding bergen county superior court new jersey judge brian martinotti proceeding nuvare mdl new jersey stay seven additional case pende state court include case coordinate state proceeding san francisco superior court california judge john munter certain state court case schedule trial merck negotiate plaintiff counsel agree settlement nuvare litigation intend resolve case file february unfiled claim retainer counsel prior date merck agree lump total settlement million provide participation settlement plaintiff eligible claimant overall certain category company certain insurance coverage available currently partially fund company legal fee insurance coverage fund settlement accordingly december company consolidated balance sheet include current liability settlement correspond current asset reflect anticipated insurance recovery propeciaproscar previously disclose merck defendant product liability lawsuit unite states involve propecia andor proscar december approximately lawsuit involve total approximately plaintiff instance spouse join plaintiff suit allege experience persistent sexual effect follow cessation treatment propecia andor proscar file merck approximately plaintiff allege propecia proscar cause cause prostate cancer male breast cancer lawsuit file federal court state court new jersey federal lawsuit consolidate pretrial purpose federal multidistrict litigation judge john gleeson eastern district new york matter pende state court new jersey consolidated judge jessica mayer middlesex county addition matter pende federal court massachusetts matter pende state court louis missouri company intend defend lawsuit vytorinzetia litigation previously disclose april merck shareholder file putative class action lawsuit federal court consolidated district new jersey caption merck inc vytorinzetia security litigation complaint allege merck defendant delay release unfavorable result enhance clinical trial efficacy vytorin merck false misleading statement expect earning know result enhance study release sale vytorin decline merck earning suffer february merck announce agreement principle plaintiff settle matter million settlement agreement execute party june approve court october settlement reflect company financial result discuss similar consolidated security class action lawsuit pende district new jersey scheringplough defendant caption scheringplough corporationenhance security litigation february merck announce agreement principle plaintiff settle matter million settlement agreement execute june approve court october settlement reflect company financial result settlement describe precede paragraph collectively enhance litigation result aggregate charge million take account anticipate insurance recovery million second quarter company pay million settlement fund company insurer subsequently pay remain million reflect additional million insurance recovery previously recognize november complaint file district new jersey merck successor scheringplough defendant certain institutional investor optedout enhance security class action scheringplough addition january complaint file district new jersey merck defendant certain institutional investor optedout vytorinzetia table content security class action merck optout complaint contain allegation similar plaintiff settle class action schere plough merck company intend dismiss complaint defend litigation governmental proceeding previously disclose merck receive civil investigative demand cid issue department justice doj address inspire company acquire merck cid advise relate false claim act investigation concern allegation inspire cause submission false claim federal health benefit program drug azasite marketing treatment indication approve food drug administration fda company cooperate doj investigation previously disclose company receive subpoena attorney office eastern district california request information civil federal health care investigation relate company marketing selling activity respect integrilin avelox january june december district court eastern district california unseal complaint employee company file federal false claim act false claim act state complaint allege company cause false claim federal state health care program promote integrilin unapproved indication provide unlawful payment benefit physician increase utilization integrilin avelox federal government state statute suit file right investigate allegation intervene suit assume responsibility direction notify court decline intervene company intend defend lawsuit previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition putative class action lawsuit file company eastern district pennsylvania behalf direct purchaser mmr vaccine predicate allegation false claim act complaint charge company misrepresented efficacy mmr vaccine violation federal antitrust law state consumer protection law company intend defend lawsuit company receive subpoena office inspector general department health human service behalf attorney office district maryland civil division doj request information relate company marketing singulair dulera certain marketing activity january present company cooperate government previously disclose company receive letter doj sec seek information activity number country reference foreign corrupt practice act company cooperate agency request believe inquiry broad review pharmaceutical industry practice foreign country company advise doj base information receive closed inquiry matter relate company future company receive additional request information doj sec company subsidiary china receive continue receive inquiry operation chinese governmental agency inquiry relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate table content commercial litigation awp litigation previously disclose company andor certain subsidiary name defendant case bring state allege manipulation pharmaceutical manufacturer average wholesale price awp public private payor calculate provider reimbursement level outcome lawsuit include substantial damage imposition substantial fine penalty injunctive administrative remedy start company settle awp case bring states alabama alaska kansas illinois kentucky louisiana oklahoma mississippi wisconsin subsidiary company continue defendant case bring state utah company reinstate defendant putative class action new jersey superior court allege behalf thirdparty payer individual manufacturer inflate drug price manipulation awps mean case originally dismiss company prejudice company intend defend lawsuit kdur antitrust litigation previously disclose june january scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upshersmith file abbreviate new drug application anda follow commencement administrative proceed federal trade commission ftc allege anticompetitive effect settlement resolve schering plough favor putative class nonclass action suit file behalf direct indirect purchaser kdur scheringplough upshersmith lederle consolidated multidistrict litigation district court district new jersey suit claim violation federal state antitrust law state statutory common law cause action seek unspecified damage april indirect purchaser voluntarily dismiss case march district court grant summary judgment defendant remain lawsuit dismiss matter entirety july circuit court appeal reverse district court grant summary judgment remand case proceeding time circuit uphold december decision district court certify certain direct purchaser plaintiff claim class action august company file petition certiorari supreme court seek review circuit decision june supreme court grant petition vacate judgment circuit remand case consideration light recent decision ftc actavis inc decision hold socalled reverse payment payment holder pharmaceutical patent party challenge patent connection settlement dispute violate antitrust law determine basis rule reason analysis september circuit return case district court proceeding accordance actavis standard coupon litigation previously disclose number private health plan file separate putative class action lawsuit company allege merck coupon program injure health insurer reduce beneficiary copayment amount allegedly cause beneficiary purchase higherpriced drug purchase increase insurer reimbursement cost action assign district judge district court district new jersey seek damage injunctive relief bar company issue coupon reduce beneficiary copay behalf putative nationwide class health insurer similar action relate manufacturer coupon program file pharmaceutical manufacturer variety federal court april district court dismiss action merck prejudice ground plaintiff fail demonstrate stand sue plaintiff subsequently file consolidated amend complaint merck file motion dismiss complaint table content sale force litigation kelli smith file complaint company united states district court district new jersey behalf putative class female sale representative putative subclass female sale representative child claim discriminatory policy practice selection promotion advancement disparate pay differential treatment hostile work environment retaliation federal state discrimination law november company file motion dismiss class claim plaintiff sought grant leave file amend complaint january plaintiff file amend complaint add additional name plaintiff company intend refile motion dismiss class allegation defend patent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company certain product company product market agreement company currently involve patent infringement litigation united states include emend injection integrilin nexium nuvare similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire merger acquisition potentially significant intangible asset impairment charge emend injection patent infringement lawsuit file united states sandoz inc sandoz respect sandozs application fda seek prepatent expiry approval market generic version emend injection lawsuit automatically stay fda approval sandozs application july adverse court decision whichever occur early june patent infringement lawsuit file united states accord healthcare inc accord healthcare inc intas pharmaceuticals ltd collectively inta respect intas application fda seek prepatent expiry approval market generic version emend injection company agree inta stay lawsuit pende outcome lawsuit sandoz integrilin february patent infringement lawsuit file jointly millennium pharmaceuticals inc united states teva parenteral medicines inc tpm respect tpm application fda seek prepatent expiry approval sell generic version integrilin october party enter settlement agreement allow tpm sell generic version integrilin begin june november patent infringement lawsuit file app pharmaceutical inc fresenius kabi usa inc collectively app respect app application fda seek prepatent expiry approval sell generic version integrilin march party enter settlement agreement allow app sell generic version integrilin begin june september patent infringement lawsuit file ben venue laboratory dba bedford laboratory bedford respect bedford application fda seek prepatent expiry approval sell generic version integrilin lawsuit automatically stay fda approval bedford application february adverse court decision whichever occur early nexium patent infringement lawsuit bring jointly astrazeneca united states follow generic company ranbaxy laboratories ltd ivax pharmaceuticals inc later acquire teva pharmaceuticals inc reddys laboratories sandoz lupin ltd hetero drugs limited unit iii torrent pharmaceuticals ltd response generic company application seek prepatent expiry approval sell generic version nexium settlement reach lawsuit term provide respective generic company bring generic version esomeprazole product market addition patent infringement lawsuit file jointly astrazeneca february united states sun pharma global fze sun pharma respect application fda seek prepatent expiry approval sell generic version nexium lawsuit settle agreement provide sun pharma entitle bring generic esomeprazole product market united states january patent infringement lawsuit file jointly astrazeneca united states hanmi usa inc hanmi relate application fda seek prepatent expiry approval sell different salt esomeprazole table content find nexium hanmi product agreement hanmi concede validity enforceability patent lawsuit party agree hanmi product infringe patent district court december claim interpretation order astrazeneca kbi appeal december court appeal federal circuit deny appeal affirm district court claim interpretation order hanmi launch esomeprazole product risk company continue believe court order incorrect consider option review finally additional patent infringement lawsuit file jointly astrazeneca united states mylan laboratories limited mylan labs actavis incwatson pharma company collectively actaviswatson relate application fda seek prepatent expiry approval sell generic version nexium mylan labs actaviswatson application fda remain stay august october respectively early adverse court decision whichever occur early nuvare december company file lawsuit warner chilcott company llc warner chilcott united states respect warner chilcotts application fda seek prepatent expiry approval sell generic version nuvare patent opposition ono pharmaceutical ono european patent broadly claim use antipd antibody company immunotherapy treatment cancer ono previously license commercial right antipd antibody bristolmyer squibb bms certain market company believe patent invalid file opposition european patent office epo seek revocation opposition division epo schedule hear june hearing panel issue preliminary opinion claim patent valid hearing panel usually render decision subject appeal close hearing patent survive proceeding similar breadth merck file action seek revoke patent relevant national court europe ono file patent infringement action company relevant national court europe time company launch approve national court determine company infringe valid claim onos patent ono entitle monetary damage include royalty future sale potentially seek injunction prevent company marketing country addition ono bms similar patent application company closely monitor pende united states japan countries company confident able market country approve prevent ono patent pende patent environmental litigation previously disclose merck involve pende litigation relate allege injury cause allege emission site merck subsidiary merce california previously disclose party litigation reach agreement intend resolve litigation subject sufficient plaintiff participation obtain party finalize settlement litigation dismiss prejudice january plaintiff litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial position result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost table content outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december purchase treasury stock include million share purchase pursuant accelerate share repurchase agreement discuss issuance primarily reflect activity sharebase compensation plan table content merck enter accelerated share repurchase asr agreement goldman sachs goldman sachs asr merck agree purchase billion merck common stock total initial delivery approximately million share merck common stock base current market price goldman sachs merck payment billion merck goldman sachs settlement asr october merck receive additional million share determine average daily volume weightedaverage price merck common stock term asr program bring total share receive merck program million asr enter pursuant share repurchase program announce noncontrolle interest connection restructure ami merck assume billion par value prefer stock dividend rate annum carry kbi include noncontrolle interest astrazeneca exercise option acquire mercks interest azlp note preferred stock obligation retire sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee addition employee nonemployee director employee certain company equity method investee grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle primarily treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus certain psus grant december employee participate dividend basis common share dividend nonforfeitable holder rsus psus issue january dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period generally year subject term applicable award total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior table content weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeit outstanding december exercisable december additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense table content pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary result plan design change approve begin january active participant merck primary define benefit pension plan accrue pension benefit new cash balance formula base age service pay interest transition period january december participant earn great benefit calculate employee legacy final average pay formula new cash balance formula year service december participant earn future benefit cash balance formula addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost pension postretirement benefit plan consist follow component pension benefit postretirement benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement net periodic benefit cost increase net periodic benefit cost pension postretirement benefit plan compare largely attributable change discount rate net periodic benefit cost attributable pension plan include table million million million connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment record pension postretirement benefit plan addition settlement record certain domestic international pension plan table content obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow postretirement pension benefit benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement fair value plan asset december benefit obligation january service cost interest cost actuarial gain loss benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability noncurrent liability fair value pension plan asset include precede table billion billion december respectively project benefit obligation pension plan billion billion respectively approximately company pension project benefit obligation december respectively relate international define benefit plan individual plan significant relative total project benefit obligation december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan pension plan project benefit obligation excess plan asset december fair value plan asset billion billion respectively benefit obligation billion billion respectively plan accumulate benefit obligation excess plan asset december fair value plan asset billion billion respectively accumulate benefit obligation billion billion respectively table content plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately respectively company pension investment year end categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument fair value companys pension plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation corporate obligation fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract derivative liability derivative plan level investment real estate fund generally value market appraisal underlie investment fund plan level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total balance january actual return plan asset relate asset hold december relate asset sell year purchase sale transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund develop market equities emerge market equity fix income obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security fix income obligation company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline table content expect contribution contribution pension plan postretirement benefit plan expect approximately million million respectively expect benefit payment expect benefit payment follow pension postretirement benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee follow amount reflect component oci postretirement pension plan benefit plan year end december net gain loss arise period prior service credit cost arise period net loss amortization include benefit cost prior service credit cost amortization include benefit cost estimate net loss gain prior service cost credit amount amortize aoci net pension postretirement benefit cost million million respectively pension plan million million respectively postretirement benefit plan table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension plan pension postretirement benefit plan information follow pension pension plan postretirement benefit plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis develop expect rate return plan longterm historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate company expect rate return range compare range pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect percentage point increase decrease effect total service interest cost component effect benefit obligation saving plan company maintain define contribution saving plan united states company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss net increase interest income compare reflect accretion time value money discount relate certain account receivables include accelerate accretion relate significant collection account receivable spain note increase interest expense compare drive issuance debt september exchange loss reflect million loss venezuelan currency devaluation february venezuelan government devalue currency bolvar fuertes vef dollar vef dollar company recognize loss exchange approximately million result remeasurement local monetary asset liability new rate january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation net present table reflect million net charge relate settlement enhance litigation note net reflect million charge relate resolution arbitration proceeding involve company right market remicade simponi note million gain disposition company interest jjmcp joint venture note million gain sale certain manufacturing facility relate asset note interest pay million million million interest pay net million receive company termination certain interest rate swap contract year note table content tax income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning tax settlement american taxpayer relief act unremitte foreign earning tax rate change amortization purchase accounting adjustment restructure health care reform legislation intangible asset impairment charge vioxx enhance litigation settlement arbitration settlement charge state taxis include tax effect contingency reserve research credit miscellaneous item foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate unite states particularly singapore ireland switzerland puerto rico operate tax incentive grant earning indefinitely reinveste yield favorable impact effective tax rate compare statutory rate foreign earning tax rate differential include impact intangible asset impairment charge amortization purchase accounting adjustment restructure cost arbitration settlement charge item present separately represent significant separately disclose pretax cost charge substantial portion item relate jurisdiction low tax rate united states impact record expense item low tax rate jurisdiction unfavorable impact effective tax rate compare statutory rate american taxpayer relief act sign law january extend research credit control foreign corporation lookthrough provision year retroactively january december company record entire benefit legislation financial statement period include date enactment impact reflect reconciliation income taxis consist year end december domestic foreign table content taxis income consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation unremitte foreign earning equity investment pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize deferred income taxis current asset asset income taxis payable deferred income taxis company net operating loss nol carryforward jurisdiction december approximately million defer taxis nol carryforward relate foreign jurisdiction individually significant approximately million valuation allowance establish foreign nol carryforward foreign defer tax asset addition company approximately million defer tax asset relate tax credit carryforward nol carryforward expect fully utilize prior expiry income taxis pay billion billion billion respectively tax benefit relate stock option exercise reflect paidin capital million million amount material table content reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation balance december amount reflect settlement irs cra discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease million month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount benefit million million million amount reflect beneficial impact tax settlement include discuss liability accrue interest penalty million billion december respectively internal revenue service irs finalize examination scheringplough tax year company unrecognize tax benefit year examination exceed adjustment relate examination period company record net million tax provision benefit irs finalize examination scheringplough tax year audit cycle company reach agreement irs adjustment income relate intercompany pricing matter income adjustment reduce nols tax credit carryforward companys reserve uncertain tax position adequate cover adjustment relate examination period additionally previously disclose company seek resolution issue raise examination irs administrative appeal process company record outofperiod net tax benefit million relate issue settle fourth quarter final resolution relate interest owe reach quarter company unrecognized tax benefit relate issue exceed settlement management conclude exclusion benefit material current prior year financial statement previously disclose canada revenue agency cra propose adjustment relate intercompany pricing matter july cra issue assessment miscellaneous audit issue tax year merck cra reach settlement year call merck pay additional canadian tax approximately million company unrecognized tax benefit relate matter exceed settlement company record net million tax provision benefit portion taxis pay expect creditable tax purpose company previously establish reserve matter resolution matter material effect company result operation financial position liquidity irs conclude examination merck federal income tax return result company require net payment approximately million company unrecognized tax benefit year examination exceed adjustment relate examination period company record net million tax provision benefit net benefit reflect decrease unrecognized tax benefit year examination partially offset increase unrecognize tax benefit year subsequent table content examination period result settlement company disagree irs treatment issue raise examination appeal matter irs administrative process addition state foreign tax examination progress significant tax jurisdiction state foreign company income tax return open examination period december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability addition company subsidiary operate puerto rico singapore tax incentive grant begin expire earning share prior company calculate earning share pursuant twoclass method earning distribute undistributed allocate common share participate security base respective right receive dividend rsus certain psus grant december generally year vest period certain management level employee meet definition participate security rsus psus issue january meet definition participate security begin company long apply twoclass method calculation earning share follow year end december basic earning common share net income attributable merck inc income allocate participate security net income allocate common shareholder average common share outstanding earning common share assume dilution net income attributable merck inc income allocate participate security net income allocate common shareholder average common share outstanding common share issuable average common share outstanding assume dilution issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income loss quarter company adopt guidance issue fasb require additional disclosure relate impact reclassification adjustment aoci net income change aoci component follow employee cumulative accumulate benefit translation comprehensive derivative investment plan adjustment income loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis relate foreign currency cash flow hedge reclassify aoci sale represent net realize gain sale availableforsale investment reclassify aoci income expense net include net amortization prior service cost actuarial gain loss include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net loss million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december include cumulative translation adjustment pretax gain approximately million relate translation impact intangible asset record conjunction merger table content segment reporting company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance include revenue equity income company relationship azlp animal health consumer care alliance segment material separate reporting include table pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sell center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet club store specialty channel accounting policy segment describe describe note table content sale company product follow year end december primary care womens health cardiovascular zetia vytorin diabete obesity januvia janumet respiratory nasonex singulair dulera asmanex womens health endocrine nuvare fosamax follistim implanon cerazette arcoxia avelox hospital specialty immunology remicade simponi infectious disease isentress cancida pegintron invanz victrelis noxafil oncology temodar emend cosopttrusopt bridion integrilin diversify brand cozaarhyzaar primaxin zocor propecia clarinex remeron claritin proscar maxalt vaccine gardasil proquadmmr iivarivax zostavax pneumovax rotateq pharmaceutical total pharmaceutical segment sale segment sale total segment sale amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health consumer care alliance alliance segment include revenue company relationship azlp revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result october company divest substantial portion thirdparty manufacturing sale note addition revenue reflect million revenue outlicense pipeline compound table content consolidated revenues geographic area derive follow year end december united states europe middle east africa japan asia pacific latin america reconciliation total segment profit consolidate income taxis follow year end december segment profit pharmaceutical segment segment total segment profit profit loss unallocate interest income interest expense equity income affiliate depreciation amortization research development amortization purchase accounting adjustment restructure cost net charge relate settlement enhance litigation arbitration settlement charge unallocated net segment profit comprise segment sale standard cost certain operating expense directly incur segment internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization purchase accounting adjustment allocate segment profit loss primarily comprise miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale divest product business supply sale unallocated net include expense corporate manufacturing cost center product intangible asset impairment charge gain loss sale business miscellaneous income expense item table content equity income affiliate depreciation amortization include segment profit follow pharmaceutical total year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization property plant equipment net geographic area locate follow year end december united states europe middle east africa asia pacific latin america japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director shareholders merck inc opinion accompany consolidated balance sheet relate consolidated statement income comprehensive income equity cash flow present fairly material respect financial position merck inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report item responsibility express opinion financial statement companys internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february table content supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder amount include net charge relate settlement certain shareholder litigation note amount include net benefit relate settlement certain federal income tax issue note amount reflect acquisitionrelated cost note impact restructuring action note table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training include financial stewardship training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december table content inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear kenneth frazier peter kellogg chairman president executive vice president chief executive officer chief financial officer item information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document page require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website wwwmerckcomaboutcodeofconductpdf merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior print copy send charge shareholder request write chief ethic compliance officer merck inc merck drive whitehouse station require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting shareholder hold require information heading compensation committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualified plan msd employee saving security plan scheringplough employee saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck sharp dohme incentive stock plan merck inc nonemployee directors stock option plan merck inc scheringplough stock incentive plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan share restrict stock unit performance share unit exclude accrue dividend merck inc schere plough stock incentive plan exclude share phantom stock defer msd employee deferral program share phantom stock defer msd director deferral program item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion audit committee beginning caption pre approval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content item